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ABSTRACT: 2-Phenylcyclopropylmethylamine (PCPMA) analogues have been
reported as selective serotonin 2C agonists. On the basis of the same scaffold, we
designed and synthesized a series of bitopic derivatives as dopamine D3R ligands.
A number of these new compounds show a high binding affinity for D3R with
excellent selectivity. Compound (1R,2R)-22e and its enantiomer (1S,2S)-22e
show a comparable binding affinity for the D3R, but the former is a potent D3R
agonist, while the latter acts as an antagonist. Molecular docking studies revealed
different binding poses of the PCPMA moiety within the orthosteric binding
pocket of the D3R, which might explain the different functional profiles of the
enantiomers. Compound (1R,2R)-30q shows a high binding affinity for the D3R
(Ki = 2.2 nM) along with good selectivity, as well as good bioavailability and brain
penetration properties in mice. These results reveal that the PCPMA scaffold may
serve as a privileged scaffold for the design of aminergic GPCR ligands.
■ INTRODUCTION
G protein-coupled receptors (GPCRs) constitute the largest
family of membrane proteins with more than 800 members.1
GPCRs are the dominant drug targets of over 30% of U.S.
FDA-approved small molecule drugs.2 The aminergic sub-
family of GPCRs is particularly rewarding drug targets that
have led to the development of many widely prescribed drugs,
and they remain the most actively pursued GPCR drug
targets.3 Endogenous ligands of aminergic GPCRs are
monoamines (i.e., dopamine, serotonin, and histamine),
which share a chemotype that features a basic nitrogen atom
attached to an aromatic moiety via a linker. Most drugs
targeting aminergic GPCRs are small molecules of a similar
chemotype or their structural derivatives. As a result, many
drugs that target aminergic GPCRs are polypharmacological
drugs that show limited selectivity across receptor subtypes.3
On the other hand, the shared chemotype among different
aminergic GPCR ligands also offers an opportunity for scaffold
repurposing of a drug targeting a specific GPCR to compounds
that show selectivity for another receptor.
2-Phenylcyclopropylmethylamines (PCPMAs) are a class of
compounds that have been reported to act as selective
serotonin 2C (5-HT2C) agonists,
4−7 which may have potential
value in treating neurological diseases such as schizophrenia
and drug addiction.8,9 Compounds 1 and 2 (Figure 1), for
example, are highly selective 5-HT2C agonists that show in vivo
efficacy in schizophrenia-like behavioral models.4,9 In our
previous screening data of compounds 1 and 2, we noticed that
they showed moderate binding affinities for the dopamine D3
receptor (D3R) (Ki = 1712 and 811 nM, respectively).
4 The
D3R is another potential drug target that is involved in central
nervous system (CNS) diseases such as drug addiction.10
Many highly selective D3R ligands have been reported in the
literature, and BP-897 (3, Figure 2) was the first compound to
enter clinical trials.11 Shown in Figure 2 are representative
D3R antagonists that share a well-known scaffold with a
primary pharmacophore that binds to the orthosteric binding
pocket (OBP) and a secondary pharmacophore binding to the
extended binding pocket (EBP), both of which are connected
with a proper linker. GPCR ligands with such a scaffold have
Figure 1. PCPMA-based serotonin 2C agonists and their binding
activity at D3R.
been depicted as “bitopic” binders.12 Interestingly, the 2-
fluoroethoxyl substitution, as in compound 1, has been used in
the D3R antagonist 4,13 and a cyclopropane can be found in
compounds such as 5,14 6,15 and 7,16 which share structural
similarities with the PCPMA scaffold of compounds 1 and 2.
Also, a cyclopropane was recently introduced into the linker of
a reported D3R bitopic agonist 8.17
Although several highly selective D3R ligands have been
reported in the literature, most compounds suffer from poor
bioavailability, low brain penetration, or unwanted side effects
in clinical trials.18,19 Therefore, there is still a need for novel
D3R selective ligands. On the basis of the cocrystal structures
of both the 5-HT2C and the D3R receptors,
20,21 we envisioned
that the small PCPMA scaffold of compounds 1 and 2 binds to
Figure 2. Representative D3R antagonists and the design of PCPMA derivatives.
Scheme 1. Synthesis of Triazole-Thiol Ether Derivativesa
aReagents and conditions: (a) methyl acrylate, Cs2CO3, MeOH, microwave, 100 °C, 30 min, 69%; (b) LiOH−H2O, THF, H2O, rt, overnight,
60%; (c) [for 13a] 2-fluoroethanol, PPh3, DEAD, THF, microwave, 60 °C, 30 min, 95%, [for 13b] EtI, K2CO3, DMF, microwave, 110 °C, 30 min,
83%, [for 13c and 13d] MeI, K2CO3, DMF, microwave, 110 °C, 30 min, 96%; (d) 2 M HCl in diethyl ether, rt, overnight, 99% or 4 M HCl in
dioxane, rt, 4−5 h, 82−94%; (e) HATU, NaHCO3, DMF, rt, 3 h, 72−90%; (f) BH3−THF in THF, reflux, 4 h, 58−92%; (g) aldehydes,
NaHB(OAc)3, THF, rt, 1 h, 24−89%.
the orthosteric pockets of both receptors, with the primary
amine group interacting with the conserved Asp3.32 residue
through a conserved salt bridge among aminergic GPCRs.3 By
attaching a D3R-preferring spacer and an EBP binding motif to
the nitrogen atom of PCPMA, we expect to obtain bitopic
PCPMA derivatives as D3R selective ligands (Figure 2).
Therefore, we started a campaign to design and synthesize
derivatives of compound 1 to discover novel D3R ligands, and
these results are reported herein. Our research shows that in
addition to its action at the 5-HT2C receptor, PCPMA may
serve as a privileged scaffold that can be repurposed for other
aminergic GPCRs.
■ RESULTS AND DISCUSSION
Chemistry. Based on the structural similarity of the
PCPMA with D3R ligands 5 and 6, we first set out to
synthesize PCPMA derivatives with the triazole-thiol ether as
the secondary pharmacophore. 4-Methyl-5-phenyl-4H-1,2,4-
triazole-3-thiol (9) was synthesized according to reported
procedures and used as the starting material.22 A Michael
addition reaction of 9 with methyl acrylate, followed by
Scheme 2. Synthesis of Amide Analoguesa
aReagents and conditions: (a) [for 19a] 2-naphthoyl chloride, NEt3, CH2Cl2, rt, 2 h, 87%; [for 19b] 1H-indole-2-carboxylic acid, HATU,
NaHCO3, DMF, rt, 2 h, 80%; [for 19c] 4-(2-pyridyl)benzoic acid, HATU, NaHCO3, DMF, rt, 2 h, 93%; (b) SO3−Py, DMSO, NEt3, CH2Cl2; (c)
[for 21a and 21b] NaBH4, NEt3, acetaldehyde, rt, 20 min, 33−34%; [for 21c and 21d] NaBH4, NEt3, propionaldehyde, rt, 20 min, 23−31%; (d)
NaHB(OAc)3, THF, rt, overnight, 37−68% for steps b and d.
Scheme 3. Synthesis of Amide Analoguesa
aReagents and conditions: (a) Ph3PCHC(O)OMe, CH2Cl2, rt, overnight, 67−98%; (b) LiOH−H2O, THF, H2O, rt, 2 h, 75−100%; (c) N,O-
dimethylhydroxylamine hydrochloride, HATU, NaHCO3, DMF, rt, overnight, 81−97%; (d) Me3S+(O)I−, NaH, DMSO, rt, overnight, 71−82%;
(e) DIBAL-H, THF, −78 °C, 2 h; (f) NaHB(AcO)3, propylamine, AcOH, rt, 44−64%; (g) NaHB(OAc)3, AcOH, THF, rt, overnight, 11−68% for
steps e and g.
saponification, afforded the carboxylic acid 11. For the
PCPMA part, Boc-protected intermediates 12a and 12b were
synthesized according to our published procedures,4 and both
were alkylated to give 13a−d via Mitsunobu reactions with 2-
fluoroethanol or direct alkylations with iodomethane or
iodoethane, as we previously reported.4,5 After the depro-
tection of the Boc, the primary amines 14a−d were coupled
with 11 to provide amides 15a−d, which were subsequently
reduced using the borane-tetrahydrofuran complex to provide
target compounds 16a−d. These secondary amines could be
further alkylated under reductive amination conditions with
simple aldehydes to afford compounds 17a−l as tertiary
amines (for details, see Experimental Section).
Compounds with an amide connection between the linker
and the secondary pharmacophore, similar to those in reported
D3R ligands 3 and 4, were also designed and synthesized. As
shown in Scheme 2, 4-aminobutan-1-ol (18) was acylated with
either acid chloride or coupled with aromatic acids to give
amides 19a−c, and the primary alcohol group was sub-
sequently oxidized to give aldehydes 20a−c. PCPMAs 14c and
14d from Scheme 1 were alkylated under reductive amination
conditions to attach ethyl or propyl substituents, thereby
affording intermediates 21a−d, which were then reacted with
the former aldehydes under reductive amination conditions to
yield compounds 22a−i (for details, see Experimental
Section).
An alternative route for similar amides is shown in Scheme
3. Briefly, starting from phenyl aldehydes 23a−f, a sequence of
Wittig reaction, ester to Weinreb amide conversion, Corey−
Chaykowsky cyclopropanation, and Weinreb amide to
aldehyde reduction provided aldehydes 28a−f.4,5 Next, the
above-mentioned aldehydes 20a−c were converted to propyl
amines 29a−c through reductive amination reactions. Further
reductive amination reactions of 28a−f with 29a−c produced
compounds 30a−r (for details, see Experimental Section).
For the PCPMA moiety of all of the new compounds, we
obtained only the trans isomers through using E olefins as the
cyclopropanation precursors, the same as our previous 5-HT2C
ligands. Of course, the racemic, trans compound is composed
of a pair of (1R,2R)- and (1S,2S)-enantiomers. In this research,
the racemic compounds 22e, 30p, 30q, and 30r were separated
by chiral HPLC to give optically pure (−)- and (+)-enan-
tiomers for further pharmacological profiling. To determine
the absolute configurations of these enantiomers, we
resynthesized the enantiomers of 22e using a method shown
in Scheme 4 (for details, see Experimental Section). Thus, the
Boc-protected intermediate 13c from Scheme 1 was separated
using chiral HPLC to give both isomers (+)-13c and (−)-13c,
which were deprotected subsequently to give HCl salts
(−)-14c and (+)-14c, respectively. We had previously
determined that the (−)-isomer has the (1R,2R) configuration
and that the (+)-isomer has the (1S,2S) configuration for very
similar compounds.4,23 Therefore, the configuration of
(−)-14c was assigned as (1R,2R) and that of (+)-14c as
(1S,2S). Both (−)-14c and (+)-14c were next converted to
(−)-21c and (+)-21c and then to (−)-22e and (+)-22e. Thus,
the configuration of (−)-22e was assigned as (1R,2R), and
(+)-22e as (1S,2S). As will be discussed below, based on
structural similarities and the consistency observed in the 5-
HT2C binding data for compounds 30p, 30q, and 30r, namely,
that the (+)-isomer shows better 5-HT2C activity, which is in
agreement with both the results from the enantiomers of 22e
and our previous results, the absolute configurations of the
(−)-isomers of 30p, 30q, and 30r were assigned as (1R,2R)
and the (+)-isomers as (1S,2S).
Structure−Activity Relationships (SARs). On the basis
of the structural similarity between the PCPMA scaffold and
the cyclopropane-containing substructures in compounds 5
and 6, we introduced the 1,2,4-triazolylthiol ether moiety as
the EBP binding motif, connected to the N atom of PCPMA
via a three-carbon spacer. As shown in Table 1, the binding
affinity of compounds 16a and 17a at D3R increased slightly
compared to PCPMA compound 1 (Ki = 1712 nM),
4 but none
of them showed significant binding selectivity among five
dopamine receptors and the 5-HT2C receptor. The N-ethyl
compound 17b showed more than a 15-fold increase in
binding affinity compared to the PCPMA compound 1 (113.1
nM versus 1712 nM). The 2-fluoroethoxy substituent on the
PCPMA part was reduced to an ethoxy group in compounds
16b, 17c, and 17d, which resulted in slight increases in binding
affinities, as can be seen by comparing 17d versus 17b, 17c
versus 17a, and 16b versus 16a. When the ethoxy substituent
on the benzene ring was further truncated to a methoxy group,
binding affinities were further increased, as can be seen from
compounds 16c, 17e, and 17f, with the last showing a Ki value
of 44.0 nM at D3R. The N-ethyl group was changed to a
propyl (17g), an isopropyl (17h), or a cyclopropylmethyl
group (17i), but none of these compounds showed an
increased affinity for D3R compared to the N-ethyl compound
17f. The fluorine atom on the left-hand benzene ring was
changed to a Cl atom in compounds 17j, 17k, and 17l, with
various N substitutions, and these compounds showed
Scheme 4. Synthesis of compounds (1R,2R)- 22e and (1S,2S)-22ea
aReagents and conditions: (a) chiral prep-HPLC separation; (b) 4 M HCl in dioxane, rt, overnight, 98%; (c) propionaldehyde, NaBH4, NEt3,
dioxane, rt, 10 min, 34−63%; (d) 20c, NaHB(AcO)3, THF, rt, overnight, 32−33%.
comparable binding affinities for D3R and moderate selectivity
against D2R, D4R, and 5-HT2C, while possessing a lower
affinity for the D1R and D5R. Taken together, the introduction
of the 1,2,4-triazolylthiol ether significantly enhanced the
compound affinity for D3R and reduced their affinity to 5-
HT2C, but compared to compound BP-897, their affinity and
selectivity still required further improvement. In our assays,
BP-897 showed a binding affinity of 3.1 nM at D3R, and 365-,
Table 1. Binding Affinities of Thiol Ethers at D1‑5 and 5-HT2C Receptors
a
aKi values were calculated from mean pKi values (mean pKi ± SEM values from at least three individual experiments are provided in Table S1).
bAll
compounds were tested as HCl salts. cNT, not tested.
80-, 205-, 395-, and 70-fold selectivity against D1R (1132 nM),
D2R (247.0 nM), D4R (634.0 nM), D5R (1223 nM), and 5-
HT2C (218.0 nM) receptors, respectively.
We then turned to a longer spacer group composed of four
carbon atoms, coupled with an amide connection to the EBP-
binding aromatic moiety. The results for these analogues are
summarized in Table 2. For the aromatic moiety, naphthyl,
indolyl, and 4-pyridylphenyl were used as they have been
reported in numerous D3R selective compounds. Comparing
compounds 22a and 22b, it can be seen that although they
show identical binding affinities to D3R, the N-propyl
substitution led to a higher selectivity profile for 22b versus
the N-ethyl substitution present in 22a, especially against D2R
and D4R. Also, in compound 22d, the N-propyl substituent
resulted in a 2-fold increase in binding affinity, compared to
that of 22c, which has an ethyl substituent. The introduction of
a 4-pyridyl phenyl group led to a further increase in binding
affinity as in compound 22e, showing a Ki value of 4.0 nM for
D3R. Moreover, compound 22e showed excellent selectivity
against all of the other dopamine receptors (439-fold against
D1R (1758 nM), 786-fold against D2R (3144 nM), 285-fold
against D4R (1142 nM), and >5000 nM for D5R). However, it
showed only moderate selectivity as the racemic mixture over
5-HT2C (53.0 nM versus 4.0 nM, or 13-fold). When the
fluorine atom was replaced by a chlorine, compound affinity
was maintained within the low nM range, but none of these
analogues were more potent, as shown for compounds 22f−i.
Next, we removed the 2-methoxy group in the PCPMA
moiety. Compounds 30a−c, which retain only the meta
fluorine substitution, showed good affinities for D3R and
excellent selectivity against D2R (Table 2). For example,
compound 30c, with a 4-pyridylphenyl EBP-binding group,
showed 45.4 nM binding affinity for D3R, but >5000 nM
binding affinity for D2R and only micromolar affinities for all
other tested receptors. When a meta chorine was introduced to
replace the fluorine atom (compounds 30d−f), similar results
were observed. Compound 30f showed 26.5 nM binding
affinity for D3R, with excellent selectivity against D2R, D4R,
and D5R and good selectivity over D1R (832 nM) and 5-HT2C
(898 nM). We then moved the halogen substitution to the
para position. As can be seen with compounds 30g−i (4-F)
and 30j−l (4-Cl), these compounds showed good binding
profiles, and in particular, compound 30l represents the best of
them, with a Ki value of 17.6 nM for the D3R and good
selectivity against the other four dopamine receptors (1308
nM at D1R, no affinity at D2R, 1413 nM at D4R, and 8844
Table 2. Binding Affinities of Amide Analogues at D1‑5 and 5-HT2C Receptors
a
aKi values were calculated from mean pKi values (mean pKi ± SEM values from at least three individual experiments are provided in Table S2).
bAll
compounds were tested as HCl salts.
nM at D5R, respectively), and moderate selectivity over 5-
HT2C (284 nM). The substitution of a para-CF3 group, as
present in compounds 5 and 6, was also introduced. As can be
seen from an examination of the data obtained for compounds
30m−o, although their binding affinities were not improved
compared to the para-F or para-Cl substitution, all three
compounds fail to bind to D2R while showing very good
selectivity against the other tested receptors. Notably, the
presence of a dichloro substitution pattern, like that present in
the drugs aripiprazole and cariprazine, provided compounds
30p−r, which show significantly enhanced binding affinities for
D3R (1.2−2.6 nM). Compound 30r, which has a Ki of 1.2 nM,
showed over 1000-fold selectivity against all other dopamine
receptors, and an 81-fold selectivity against 5-HT2C (Ki = 97.7
nM). The overall profiles of 30p and 30q were also very
encouraging. On the basis of these results, we selected
compounds 22e, 30p, 30q, and 30r for further studies.
Influence of Chirality on Binding Affinity and
Functional Activity. The significance of chirality is a critical
consideration in medicinal chemistry and has also been
showcased in previous D3R ligand discovery.17 With respect
to the chiral centers on the PCPMA skeleton, although all
compounds were synthesized as the trans isomers, they were
tested as a mixture of (1R,2R) and (1S,2S) isomers in our
primary screening. We thus selected the four best compounds,
22e, 30p, 30q, and 30r, for chiral separations and further
pharmacological profiling. Chiral separations were conducted
using chiral HPLC columns, and the absolute configurations of
all the isomers were assigned as discussed above. All four pairs
of enantiomers were profiled in the same binding assays against
the dopamine receptors and the 5-HT2C receptor. As can be
seen in Table 3, the (1R,2R) enantiomers showed slightly
better binding affinities for D3R than the (1S,2S) for
compounds 30p, 30q, and 30r (4.4 versus 20.8 nM, 2.2
versus 12.8 nM, and 1.5 versus 5.3 nM, respectively). For
compound 22e, the enantiomers displayed equal affinities for
D3R (4.1 versus 3.8 nM). Interestingly, the enantiomers of all
four compounds showed comparable affinities for all dopamine
receptors within each pair, but their affinities for 5-HT2C were
different. The (1R,2R) enantiomers showed 3−22× weaker 5-
HT2C binding affinity than their (1S,2S) isomers, consistent
with the results of our previous PCPMA analogues.4 It would
appear that the D3R has little binding preference for the chiral
conformations of the PCPMA unit, while the 5-HT2C is more
sensitive.
These enantiomers were further profiled for their functional
activity at the D3 and 5-HT2C receptors. As shown in Table 4
and Figure 3A, for compounds 30p−r, both enantiomers
Table 3. Enantiomer Activity of Selected Compoundsa
aKi values were calculated from mean pKi values (mean pKi ± SEM values from at least three individual experiments are provided in Table S3).
bAll
compounds were tested as HCl salts.
showed full or partial agonist activity at D3R with comparable
potency between each pair of enantiomers. Interestingly,
(1R,2R)-22e showed very potent agonist activity (EC50 = 3.6
nM, Emax = 77.9%), while (1S,2S)-22e showed no activity in
the agonist mode but behaved as a potent antagonist of D3R
(Ki = 16.7 nM). At 5-HT2C (Figure 3C−D), both 22e
enantiomers were weak antagonists with micromolar activity.
For compounds 30p−r, (1S,2S) isomers were partial agonists
with low potency while the (1R,2R) isomers showed very weak
antagonist activity at 5-HT2C receptors. These results reveal
that the selected compounds show better selectivity for D3R
versus 5-HT2C in the functional assays compared to their
selectivity as determined from their binding affinities.
Furthermore, these enantiomers were tested at 5-HT2A and
5-HT2B receptors for their agonist activity to exclude potential
hallucinogenic or valvulopathic side effects related to these
receptors, respectively. All enantiomers showed very weak and
only partial 5-HT2A agonist activity, and no 5-HT2B agonism
was observed (see Table S1).
The Tango assay was also performed at D3R to evaluate
compound activity for β-arrestin2 recruitment (Table 4 and
Figure 3B). Compared to their Gi/o activity, most compounds
showed very weak β-arrestin2 recruitment at D3R. In
particular, compounds (1S,2S)-22e, (1R,2R)-30p, (1R,2R)-
30q, and (1R,2R)-30r showed no measurable activity in the
Tango assay, indicating their preference for the G protein
signaling.24
Molecular Docking Studies. To understand the molec-
ular basis of the binding profiles of these new compounds,
especially compounds (1R,2R)- and (1S,2S)-22e, we carried
out molecular docking studies on them using Schrödinger’s
Maestro program. (1R,2R)- and (1S,2S)-22e, as well as
Table 4. Functional Data of Selected Compounds at D3R
and 5-HT2C
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Figure 3. Functional characterization of lead compounds at D3 dopamine receptors (A, B) and 5-HT2C receptors (C, D). (A) Inhibition of cAMP
production at D3 (Gi-agonist activity), (B) β-arrestin2 recruitment (Tango agonist activity), and calcium mobilization at 5-HT2C (Gq agonist
activity in panel C and antagonist activity in panel D) represented means ± SEM from a minimum of 3 independent assays, each in triplicate or
quadruplicate. The reference agonist (5-HT) was used at a final concentration of 1 nM in antagonist assays (D), in which mesulergine served as a
reference antagonist.
eticlopride, were docked to the antagonist-bound structure of
D3R (PDB code: 3PBL).21 The salt bridge between the
positive charged tertiary amine and the carboxylate of D1103.32
was observed for all three ligands (Figure 4A), which has been
reported as highly conserved for most aminergic receptors.3
Consistent with previous research21,25,26 and our expectations,
the PCPMA moiety of both (1R,2R)- and (1S,2S)-22e
occupies the OBP of D3R, in good alignment with eticlopride,
while the attachment to the PCPMA extends into the EBP.
Notably, although both (1R,2R)- and (1S,2S)-22e fit nicely in
the OBP with the substituted benzene rings forming π−π
stacking and hydrophobic interactions, the orientations of the
substituted phenyl ring of (1R,2R)- and (1S,2S)-22e are quite
different. For (1R,2R)-22e, the 2-methoxy substituent on the
benzene ring is deeply buried within the OBP, forming
hydrophobic contacts with C1143.36, S1965.46, and F3466.52,
while the 2-methoxy group of the antagonist (1S,2S)-22e flips
up toward the extracellular side. As a result, for antagonist
(1S,2S)-22e, the cyclopropane linker between the benzene ring
and the protonated N overlays perfectly with the amide linker
of eticlopride, while for the agonist (1R,2R)-22e the
cyclopropane points to another direction due to the flip of
the benzene ring. Since a structure of the active state of D3R is
currently unavailable, the docking of agonist (1R,2R)-22e to
the active state of D3R has not been conducted. This flip of the
benzene ring in the inactive conformation of D3R might
explain the different functional results observed for these
enantiomers.
A further observation from the functional data is that, while
the PCPMA compound 2 is a potent agonist of 5-HT2C, the
Figure 4. Comparison of binding poses of D3R antagonist eticlopride, (1R,2R)-22e and (1S,2S)-22e. The receptor structure employed for the
molecular docking study was extracted from the crystal structure of the eticlopride−D3R complex (PDB code: 3PBL). Carbon atoms of eticlopride,
(1R,2R)-22e and (1S,2S)-22e are colored in green, orange, and cyan, respectively.
Figure 5. Comparison of binding poses of 5HT2C representative agonists (A) and antagonists (B). The receptor structures used in the molecular
docking studies were extracted from the crystal structures of the ergotamine−5HT2C complex (PDB code: 6BQG) and the ritanserin−5HT2C
complex (PDB code: 6BQH). Carbon atoms of ergotamine, compound 2, ritanserin, and (1S,2S)-22e are colored in orange, pink, green, and cyan,
respectively.
bitopic derivative (1S,2S)-22e turned out to be a moderate
antagonist (IC50 = 858.5 nM). For the di-Cl substituted
compounds 30p, 30q, and 30r, although the (1S,2S) eutomers
showed partial agonist activity, their efficacy was very low (Emax
= 30.3%, 44.2%, and 51.9%, respectively). To explore the
molecular basis for this conversion from PCPMA-based 5-
HT2C agonists to bitopic antagonists/weak partial agonists, we
also performed molecular docking of compounds 2 and
(1S,2S)-22e to the crystal structures of 5-HT2C. Thus,
compound 2 was docked to the ergotamine-bound active
structure of 5-HT2C (PDB code: 6BQG), while compound
(1S,2S)-22e was docked to the ritanserin-bound inactive
structure of 5-HT2C (PDB code: 6BQH).
20 As shown in Figure
5, all of these ligands form salt bridges between the protonated
nitrogen atoms of the ligands and D1343.32, a key interaction
for aminergic GPCR ligands. In the cocrystal structures, the
deep binding pose of ritanserin, with the phenyl ring inserted
more deeply than the ergoline scaffold of ergotamine, was
proposed as a possible explanation for its antagonistic
activity.20 In our docking poses, in comparison to the
PCPMA compound 2, the bitopic derivative (1S,2S)-22e
inserts approximately one helical turn deeper into the TM
bundle, which likely explains its antagonistic action at the 5-
HT2C receptor. The fluorophenyl groups form halogen-
aromatic interactions with F2235.47and F3206.44, aromatic
edge-to-face π−π stacking with F3286.52 and W3246.48, and
hydrophobic interactions with T1393.37, S1383.36, and I1423.40.
Similar to ritanserin, the deep binding pose of (1S,2S)-22e
likely prevents the conformational changes of the toggle switch
in TM6 (W3246.48) and rotamer switches in the conserved P−
I−F motif,20 thus stabilizing the inactive state of 5-HT2C. It
may thus be postulated that the attachment of the four carbon-
linker and the EBP-binding motifs to the PCPMA scaffold
results in a deeper binding mode for compound (1S,2S)-22e,
thus leading to its antagonism of the receptor.
Pharmacokinetic and Brain Penetration Properties.
On the basis of their good binding affinity and selectivity for
D3R, we selected compounds (1R,2R)-22e, (1R,2R)-30p,
(1R,2R)-30q, and (1R,2R)-30r for further PK profiling in male
ICR mice. As shown in Table 5, intravenous (iv)
administration (5 mg/kg) of these compounds showed
moderate exposure in plasma, with high clearance. Oral
administration (10 mg/kg) of compounds (1R,2R)-22e,
(1R,2R)-30p, and (1R,2R)-30r gave very low bioavailability
(3.8%, 6.6%, and 13.0% respectively), but compound (1R,2R)-
30q showed a reasonably good oral bioavailability of 34.1%.
Furthermore, this compound showed an oral half-life of 4.1 h
and an MRT of 6 h.
In our previous studies, PCPMA analogues showed very
high brain penetration as 5-HT2C agonists.
4,5 Accordingly,
these four selected compounds were further tested for their
brain penetration properties in ICR mice. Brain and plasma
drug concentrations after both iv and oral dosing were
measured at 0.5 and 2.0 h time points, and brain/plasma
ratios were calculated. As shown in Table 5, all four
compounds showed good brain penetration, although sig-
nificant differences were observed for their brain concen-
trations following oral dosing, which can be attributed to their
different overall PK profiles. Thus, the brain exposures of
compounds (1R,2R)-22e, 30p, and 30r were very low
following oral dosing, despite good brain/plasma ratios. As
for compound (1R,2R)-30q, high brain/plasma ratios were
observed for both iv and oral dosing, at both time points.
Calculated concentrations of 108.6 (51.3 ng/mL) and 338.6
nM (160 ng/mL) were observed at 0.5 and 2.0 h, respectively.
Moderate but long-lasting brain exposure could be expected
for compound (1R,2R)-30q, given the relatively long half-life
and MRT observed in PK studies. The overall PK and brain
penetration profiles of (1R,2R)-30q support it as a good
candidate for further in vivo studies in disease models.
Polypharmacological Profiling at Other Aminergic
GPCRs. As mentioned above, polypharmacology is a common
feature of many aminergic GPCR ligands. To further profile
the binding selectivity of our bitopic D3R ligands, we selected
compounds (1R,2R)-22e and (1R,2R)-30q and screened them
against 29 other aminergic GPCRs, including serotonin,
adrenaline, histamine, and muscarinic receptors. Compounds
(1R,2R)-22e and (1R,2R)-30q show weak binding affinity for
most receptors (pKi < 6) and modest binding for 5-HT1A, 5-
HT2B, α2A, α2C, and H1R (see Table S4). These data show that
compounds (1R,2R)-22e and (1R,2R)-30q have good
selectivity for the D3R against most other aminergic GPCRs.
Table 5. PK and Brain Penetration Properties of Selected Compounds in ICR Micea
(1R,2R)-22e (1R,2R)-30p (1R,2R)-30q (1R,2R)-30r
parameters iv po iv po iv po iv po
Cmax (ng/mL) 43.2 37.3 63.9 118
tmax (h) 0.25 0.25 1.00 0.50
t1/2 (h) 0.437 2.64 1.51 2.08 3.12 4.11 0.576 2.12
AUC0−t (h·ng/mL) 660 49.5 616 81.1 629 428 976 254
CL (mL/min/kg) 126 134 117 84.8
MRT(h) 0.415 3.72 2.58 2.59 3.40 6.00 0.808 2.77
VdSS (L/kg) 3.13 20.8 23.8 4.11
F 3.8% 6.6% 34.1% 13.0%
brain concentration at 0.5 h (ng/mL) 530 ± 37 8.21 ± 2 3424 ± 286 23.2 ± 4.0 833 ± 187 51.3 ± 21 980 ± 164 26.7 ± 9.0
plasma concentration at 0.5 h (ng/
mL)
446 ± 15 16.8 ± 5.0 270 ± 22 28.4 ± 15 215 ± 13 35.5 ± 7.0 511 ± 67 118 ± 7.0
brain/plasma ratio at 0.5 h 1.19 0.49 12.7 0.82 3.88 1.45 1.92 0.23
brain concentration at 2.0 h (ng/mL) 19.4 ± 11 6.57 913 ± 97 23.2 ± 4.0 543 ± 99 160 ± 45 227 ± 17.0 9.1 ± 5.3
plasma concentration at 2.0 h (ng/
mL)
12.7 ± 3.1 8.4 ± 2.4 82.6 ± 9.7 16.4 ± 3.5 94.8 ± 19.3 67.7 ± 20 118 ± 16.5 44.1 ± 7.6
brain/plasma ratio at 2.0 h 1.53 0.79 11.1 1.61 5.72 2.36 1.93 0.207
aFor all four compounds, the iv dose is 5 mg/kg, and the po dose is 10 mg/kg.
■ CONCLUSIONS
In the past decade, cocrystal structures of aminergic GPCRs
have greatly facilitated our understanding of ligand−receptor
interactions at these receptors as well as the structure-based
drug design of novel GPCR ligands. Starting from the PCPMA
scaffold, we have designed and synthesized a series of bitopic
derivatives that possess excellent binding affinities for the D3R
with good selectivity against other dopamine receptors. Among
the optimized compounds, (1R,2R)-22e showed a binding
affinity of 4.1 nM for D3R, with 1195-, 329-, and 140-fold
selectivity over D1R (4898 nM), D2R (1349 nM), and D4R
(575 nM), while possessing weak 5-HT2C affinity (1122 nM)
and no affinity for the D5R. Its enantiomer, (1S,2S)-22e,
displayed a comparable affinity for D3R (Ki = 3.8 nM), with
282-, 324-, and 224-fold selectivity against D1R (1071 nM),
D2R (1230 nM), and D4R (851 nM), no affinity for D5R, and
moderate selectivity over 5-HT2C (Ki = 50.1 nM). Notably,
although the enantiomers showed almost identical binding
affinity for D3R, (1R,2R)-22e behaved as a potent agonist
(EC50 = 3.6 nM), while (1S,2S)-22e showed potent antagonist
activity (Ki = 16.7 nM) in the Gi-cAMP assays. Molecular
docking results revealed that these enantiomers adopt different
binding poses in the D3R OBP, which emphasizes the
importance of compound chirality in medicinal chemistry.
Due to high lipophilicity and large molecular weight, most
bitopic ligands suffer from poor PK properties and low brain
penetration. In this study, we determined that compound
(1R,2R)-30q, which shows a high binding affinity for the D3R
(Ki = 2.2 nM) with excellent selectivity against all other
dopamine receptors (627-, 244-, and 476-fold against D1R,
D2R, and D4R, no binding affinity for D5R) and most other
aminergic GPCRs, is a bioavailable (F = 34.1%) and brain
penetrant D3R partial agonist (EC50 = 87.0 nM, Emax = 40.7%).
The overall profile of (1R,2R)-30q supports further evaluation
in animal studies.
■ EXPERIMENTAL SECTION
General. All commercial chemicals and solvents were used as
obtained without further purification. Microwave reactions were run
in a Biotage Initiator microwave reactor. Synthetic intermediates were
purified on 230−400 mesh silica gel by Teledyne CombiFlash Rf flash
chromatography. 1H NMR spectra were recorded on a Bruker
AVANCE-II or AVANCE-III spectrometer at 500, 600, or 800 MHz.
13C NMR spectra were recorded on an AVANCE-III spectrometer at
201 MHz. NMR chemical shifts were reported in δ (ppm) using
residual solvent peaks as standards (CDCl3−7.26 (H), 77.16 (C);
CD3OD−3.31 (H), 49.00 (C); DMSO-d6−2.50 (H), 39.52 (C)).
Mass spectra were measured using an LCMS-IT-TOF (Shimadzu)
mass spectrometer in ESI mode. The purity of all final compounds
was determined by analytical HPLC (Shim-pack GIST C18 column
(250 mm × 4.6 mm, particle size 5 μM); 0.05% TFA in H2O/0.05%
TFA in MeOH gradient eluting system; flow rate = 1.0 mL/min). The
purity of all final compounds is over 95%. Optical rotation values were
recorded on a Rudolph Autopol VI automatic polarimeter (λ = 589
nm, temperature = 20 °C).
Methyl 3-((4-Methyl-5-phenyl-4H-1,2,4-triazol-3-yl)thio)-
propanoate (10). A mixture of 9 (1.0 g, 5.26 mmol), methyl acrylate
(6.0 mL), and Cs2CO3 (3.43 g, 10.52 mmol) was heated at 100 °C for
30 min under microwave radiation. After being cooled to room
temperature, the mixture was taken up in ethyl acetate and washed
with water. The organic layer was separated, dried, and concentrated.
The resulting residue was purified by flash chromatography (0−20%
ethyl acetate in petroleum ether) to give the title product as a white
solid (4.0 g, 69%). 1H NMR (800 MHz, CDCl3): δ 7.59−7.51 (m,
5H), 4.58 (t, J = 7.4 Hz, 2H), 3.72 (s, 3H), 3.66 (s, 3H), 2.96 (t, J =
7.4 Hz, 2H). HRMS (ESI): m/z calcd for C13H16N3O2S
+ [M + H]+,
278.0958; found, 278.0953.
3-((4-Methyl-5-phenyl-4H-1,2,4-triazol-3-yl)thio)propanoic Acid
(11). Compound 10 (4.0 g, 21.0 mmol) was dissolved in a mixture of
THF (50 mL)/H2O (20 mL), and LiOH−H2O (4.2 g, 100 mmol)
was then added. The mixture was stirred at room temperature
overnight. A solution of 3 M HCl (aq) was added to acidify the
mixture, and ethyl acetate was then added. The organic layer was
separated, washed with water, dried, and concentrated. The residue
was purified by flash chromatography (0−10% methanol in
dichloromethane) to give the title compound as a white solid (2.26
g, 60%). 1H NMR (800 MHz, CD3OD): δ 7.68−7.66 (m, 2H), 7.58−
7.52 (m, 3H), 4.47 (t, J = 7.3 Hz, 2H), 3.60 (s, 3H), 2.89 (t, J = 7.3
Hz, 2H). 13C NMR (201 MHz, CD3OD): δ 174.21, 168.33, 152.21,
132.06, 130.10 (2C), 129.81 (2C), 127.08, 46.09, 33.47, 33.06.
HRMS (ESI): m/z calcd for C12H14N3O2S
+ [M + H]+, 264.0801;
found, 264.0830.
tert-Butyl ((2-(5-Fluoro-2-(2-fluoroethoxy)phenyl)cyclopropyl)-
methyl)carbamate (13a). A mixture of tert-butyl ((2-(5-fluoro-2-
hydroxyphenyl)cyclopropyl) methyl)carbamate (100 mg, 0.36 mmol),
2-fluoroethanol (52 μL, 0.89 mmol), and PPh3 (233 mg, 0.89 mmol)
in dry THF (8 mL) was cooled to 0 °C. Diethyl azodicarboxylate
(140 μL, 0.89 mmol) was added dropwise. The reaction mixture was
irradiated under microwave at 60 °C for 30 min. The mixture was
evaporated to dryness to give a crude product, which was purified by
flash chromatography (0−10% ethyl acetate in petroleum ether) to
give the title compound as a colorless oil (110 mg, 95%). 1H NMR
(800 MHz, CDCl3): δ 6.82 (td, J = 8.4, 3.1 Hz, 1H), 6.77 (dd, J = 8.9,
4.6 Hz, 1H), 6.62 (dd, J = 9.3, 3.1 Hz, 1H), 5.00 (s, 1H), 4.90−4.74
(m, 2H), 4.31−4.18 (m, 2H), 3.51 (d, J = 13.3 Hz, 1H), 2.81 (dd, J =
13.4, 8.5 Hz, 1H), 1.96−1.92 (m, 1H), 1.46 (s, 9H), 1.11−1.04 (m,
1H), 1.02−0.99 (m, 1H), 0.87−0.83 (m, 1H). HRMS (ESI): m/z
calcd for C17H23F2NO3Na
+ [M + Na]+, 350.1538; found, 350.1548.
tert-Butyl ((2-(2-Ethoxy-5-fluorophenyl)cyclopropyl)methyl)-
carbamate (13b). A mixture of tert-butyl ((2-(5-fluoro-2-
hydroxyphenyl)cyclopropyl)methyl)carbamate (300 mg, 1.07
mmol), EtI (256 μL, 3.21 mmol), and K2CO3 (442 mg, 3.21
mmol) in DMF (10 mL) was irradiated under a microwave at 110 °C
for 30 min. The mixture was diluted with ethyl acetate and washed
with water. The organic layers were then combined and washed with
brine. The volatiles were removed to give a crude product, which was
purified by flash chromatography (0−10% ethyl acetate in petroleum
ether) to give the title compound as a colorless oil (275 mg, 83%). 1H
NMR (800 MHz, CDCl3): δ 6.81 (td, J = 8.4, 3.1 Hz, 1H), 6.75 (dd, J
= 8.9, 4.5 Hz, 1H), 6.63 (dd, J = 9.3, 3.1 Hz, 1H), 5.15 (s, 1H), 4.15−
4.02 (m, 2H), 3.62−3.55 (m, 1H), 2.75−2.68 (m, 1H), 1.88−1.84
(m, 1H), 1.51 (t, J = 7.0 Hz, 3H), 1.46 (s, 9H), 1.04−0.99 (m, 2H),
0.84−0.80 (m, 1H). HRMS (ESI): m/z calcd for C17H24FNO3Na+
[M + Na]+, 332.1632; found, 332.1629.
tert-Butyl ((2-(5-Fluoro-2-methoxyphenyl)cyclopropyl)methyl)-
carbamate (13c). A mixture of tert-butyl ((2-(5-fluoro-2-
hydroxyphenyl)cyclopropyl)-methyl)carbamate (281 mg, 1.0 mmol),
MeI (213 mg, 1.5 mmol), and K2CO3 (828 mg, 6.0 mmol) in DMF
(8 mL) was irradiated under microwave at 110 °C for 30 min. The
mixture was diluted with ethyl acetate and washed with water. The
organic layer was separated, dried, and concentrated. The resulting
residue was purified by flash chromatography (0−10% ethyl acetate in
petroleum ether) to give the title compound as a colorless oil (284
mg, 96%). 1H NMR (800 MHz, CDCl3): δ 6.84 (td, J = 8.5, 3.1 Hz,
1H), 6.75 (dd, J = 9.0, 4.5 Hz, 1H), 6.64 (dd, J = 9.3, 3.1 Hz, 1H),
5.28 (s, 1H), 3.88 (s, 3H), 3.56 (s, 1H), 2.76−2.66 (m, 1H), 1.87−
1.81 (m, 1H), 1.47 (s, 9H), 1.05−0.97 (m, 2H), 0.88−0.81 (m, 1H).
HRMS (ESI): m/z calcd for C16H22FNO3Na
+ [M + Na]+, 318.1476;
found, 318.1484.
(2 - (5-F luoro-2- (2-fluoroethoxy)pheny l )cyc lopropy l ) -
methanamine Hydrochloride (14a). A solution of 13a (203 mg, 0.62
mmol) in 4 M HCl (g) in dioxane (8 mL) was stirred at room
temperature for 5 h. The solvent was evaporated, and the residue was
suspended in a mixture of ethyl acetate and petroleum ether (v/v = 1/
2, 5.0 mL) and stirred for 15 min. The precipitate was collected by
filtration, washed with ethyl acetate (3 mL), and dried under a
vacuum to give the title compound as a white solid (134 mg, 82%).
1H NMR (500 MHz, CD3OD): δ 6.96−6.87 (m, 2H), 6.76 (dd, J =
9.4, 3.0 Hz, 1H), 4.87−4.70 (m, 2H), 4.34−4.18 (m, 2H), 3.05−2.97
(m, 2H), 2.19−2.13 (m, 1H), 1.27−1.22 (m, 1H), 1.21−1.15 (m,
1H), 1.05−1.00 (m, 1H). HRMS (ESI): m/z calcd for C12H16F2NO+
[M + H]+, 228.1194; found, 228.1220.
(2-(2-Ethoxy-5-fluorophenyl)cyclopropyl)methanamine Hydro-
chloride (14b). The title compound was prepared from 13b using a
similar method as described for 14a. White solid. 1H NMR (500
MHz, CD3OD): δ 6.91−6.82 (m, 2H), 6.70 (dd, J = 9.5, 2.8 Hz, 1H),
4.11−4.02 (m, 2H), 3.08−2.93 (m, 2H), 2.17−2.12 (m, 1H), 1.43 (t,
J = 7.0 Hz, 3H), 1.34−1.27 (m, 1H), 1.12−1.08 (m, 1H), 1.05−1.00
(m, 1H). HRMS (ESI): m/z calcd for C12H17FNO
+ [M + H]+,
210.1289; found, 210.1285.
(2-(5-Fluoro-2-methoxyphenyl)cyclopropyl)methanamine Hy-
drochloride (14c). To a solution of 13c (196 mg, 0.66 mmol) in
THF (4 mL) was added 2 M HCl (g) in Et2O (4 mL) and stirred at
room temperature overnight. The volatiles were removed to give a
white solid (153 mg, 99%), which was used directly in the next step.
1H NMR (800 MHz, CD3OD): δ 6.92−6.87 (m, 2H), 6.72 (dd, J =
9.3, 2.9 Hz, 1H), 3.86 (s, 3H), 3.07 (dd, J = 13.0, 7.1 Hz, 1H), 2.93
(dd, J = 13.1, 8.0 Hz, 1H), 2.14−2.10 (m, 1H), 1.28−1.22 (m, 1H),
1.14−1.09 (m, 1H), 1.04−1.00 (m, 1H). HRMS (ESI): m/z calcd for
C11H15FNO
+ [M + H]+, 196.1132; found, 196.1135.
(2-(5-Chloro-2-methoxyphenyl)cyclopropyl)methanamine Hy-
drochloride (14d). The title compound was prepared using 13d at
the starting material, in the same manner as described for 14c. White
solid (yield 99%). 1H NMR (800 MHz, CD3OD): δ 7.17 (dd, J = 8.7,
2.6 Hz, 1H), 6.97 (d, J = 2.6 Hz, 1H), 6.93 (d, J = 8.7 Hz, 1H), 3.88
(s, 3H), 3.09 (m, 1H), 2.94 (m, 1H), 2.10 (m, 1H), 1.30−1.24 (m,
1H), 1.12 (m, 1H), 1.03 (m, 1H). HRMS (ESI): m/z calcd for
C11H15ClNO
+ [M + H]+, 212.0837; found, 212.0834.
N-((2-(5-Fluoro-2-(2-fluoroethoxy)phenyl)cyclopropyl)methyl)-3-
((4-methyl-5-phenyl-4H-1,2,4-triazol-3-yl)thio)propanamide (15a).
To a mixture of 14a (120 mg, 0.46 mmol), 11 (132 mg, 0.50 mmol),
and HATU (260 mg, 0.68 mmol) in DMF (10 mL) was added
NaHCO3 (115 mg, 1.37 mmol). The mixture was stirred at room
temperature for 3 h. The mixture was then diluted with ethyl acetate
and washed with water and brine. The organic layer was dried and
concentrated to give a crude product, which was purified by flash
chromatography (0−3% methanol in dichloromethane) to give the
title compound as a white solid (194 mg, 90%). 1H NMR (500 MHz,
CD3OD): δ 7.67−7.63 (m, 2H), 7.59−7.50 (m, 3H), 6.87 (dd, J =
8.9, 4.7 Hz, 1H), 6.80 (td, J = 8.5, 3.1 Hz, 1H), 6.54 (dd, J = 9.7, 3.0
Hz, 1H), 4.79 (t, J = 4.0 Hz, 1H), 4.69 (t, J = 4.0 Hz, 1H), 4.52 (t, J =
6.9 Hz, 2H), 4.26−4.16 (m, 2H), 3.60 (s, 3H), 3.22 (ddd, J = 20.8,
12.8, 6.8 Hz, 2H), 2.79 (t, J = 6.9 Hz, 2H), 2.05−1.99 (m, 1H), 1.19−
1.12 (m, 1H), 0.87−0.80 (m, 2H). HRMS (ESI): m/z calcd for
C24H27F2N4O2S
+ [M + H]+, 473.1817; found, 473.1815.
N-((2-(2-Ethoxy-5-fluorophenyl)cyclopropyl)methyl)-3-((4-meth-
yl-5-phenyl-4H-1,2,4-triazol-3-yl)thio)propanamide (15b). The title
compound was prepared from 14b using a similar method as
described for 15a as a white solid (yield 72%). 1H NMR (800 MHz,
CD3OD): δ 7.68 (d, J = 7.9 Hz, 2H), 7.59 (t, J = 7.3 Hz, 1H), 7.55 (t,
J = 7.6 Hz, 2H), 6.85 (dd, J = 8.9, 4.7 Hz, 1H), 6.80 (td, J = 8.5, 3.0
Hz, 1H), 6.53 (dd, J = 9.6, 3.0 Hz, 1H), 4.55 (t, J = 7.0 Hz, 2H),
4.07−4.00 (m, 2H), 3.62 (s, 3H), 3.35 (dd, J = 13.5, 6.2 Hz, 1H),
3.14 (dd, J = 13.8, 7.2 Hz, 1H), 2.82 (t, J = 7.0 Hz, 2H), 2.06−2.01
(m, 1H), 1.42 (t, J = 7.0 Hz, 3H), 1.22−1.16 (m, 1H), 0.88−0.84 (m,
1H), 0.83−0.79 (m, 1H). HRMS (ESI): m/z calcd for
C24H28FN4O2S
+ [M + H]+, 455.1912; found, 455.1906.
N-((2-(5-Fluoro-2-methoxyphenyl)cyclopropyl)methyl)-3-((4-
methyl-5-phenyl-4H-1,2,4-triazol-3-yl)thio)propanamide (15c).
The title compound was prepared from 14c using a similar method
as described for 15a as a white solid (yield 72%). 1H NMR (800
MHz, CD3OD): δ 7.67−7.49 (m, 5H), 6.86−6.78 (m, 2H), 6.53 (dd,
J = 9.5, 3.1 Hz, 1H), 4.53 (t, J = 7.0 Hz, 2H), 3.82 (s, 3H), 3.60 (s,
3H), 3.21 (d, J = 6.9 Hz, 2H), 2.86−2.74 (m, 2H), 2.00−1.96 (m,
1H), 1.19−1.11 (m, 1H), 0.86−0.76 (m, 2H). HRMS (ESI): m/z
calcd for C23H26FN4O2S
+ [M + H]+, 441.1755; found, 441.1749.
N-((2-(5-Chloro-2-methoxyphenyl)cyclopropyl)methyl)-3-((4-
methyl-5-phenyl-4H-1,2,4-triazol-3-yl)thio)propanamide (15d).
The title compound was prepared from 14d using a similar method
as described for 15a as a yellow solid (yield 88%). 1H NMR (800
MHz, CDCl3): δ 7.58−7.52 (m, 3H), 7.51 (m, 2H), 7.12 (dd, J = 8.7,
2.6 Hz, 1H), 6.84 (d, J = 2.6 Hz, 1H), 6.76 (d, J = 8.7 Hz, 1H), 6.43
(s, 1H), 4.67−4.58 (m, 2H), 3.89 (s, 3H), 3.68−3.62 (m, 1H), 3.64
(s, 3H), 2.96−2.83 (m, 3H), 1.85 (m, 1H), 1.05−0.95 (m, 2H), 0.85
(m, 1H). HRMS (ESI): m/z calcd for C23H26ClN4O2S




drochloride (16a). To a solution of 15a (168 mg, 0.36 mmol) in
anhydrous THF (10 mL) was added a solution of BH3−THF
complex in THF (1 M, 1.4 mL, 1.4 mmol) dropwise at 0 °C under
argon. The solution was then heated to reflux and stirred for 4 h. The
reaction was quenched by slowly adding MeOH (1 mL) and then 3 M
aqueous HCl (1 mL), followed by refluxing for 30 min. The reaction
mixture was cooled to room temperature, and then saturated aqueous
NaHCO3 was added slowly to adjust to pH 8−10. The mixture was
extracted with ethyl acetate. The extracts were combined, washed with
brine, dried over anhydrous Na2SO4, and concentrated. The crude
product was purified by flash chromatography (0−5% methanol in
dichloromethane) to give a colorless oil (112 mg, 69%). The oil was
then dissolved in dichloromethane, and 2 M HCl in diethyl ether (2
mL) was added; the mixture was stirred at room temperature for 15
min. Volatiles were removed by evaporation to give the title
compound as a white solid. HPLC: 99.3% (λ = 254 nm, tR = 14.7
min). 1H NMR (500 MHz, CD3OD): δ 7.72 (d, J = 7.0 Hz, 2H),
7.66−7.57 (m, 3H), 6.97−6.87 (m, 2H), 6.75 (dd, J = 9.4, 2.5 Hz,
1H), 4.88−4.69 (m, 2H), 4.45 (t, J = 6.4 Hz, 2H), 4.33−4.19 (m,
2H), 3.66 (s, 3H), 3.24−3.14 (m, 4H), 2.36−2.28 (m, 2H), 2.28−
2.21 (m, 1H), 1.37−1.29 (m, 1H), 1.24−1.17 (m, 1H), 1.10−1.04
(m, 1H). 13C NMR (201 MHz, CD3OD): δ 168.83, 158.86 (d, JCF =
237.6 Hz), 154.78, 152.82, 132.83 (d, JCF = 7.5 Hz), 132.27, 130.20
(2C), 129.84 (2C), 126.93, 114.18 (d, JCF = 24.2 Hz), 114.15, 114.06
(d, JCF = 23.0 Hz), 83.48 (d, JCF = 168.0 Hz), 69.70 (d, JCF = 19.0
Hz), 52.96, 46.83, 45.73, 33.65, 26.39, 18.53, 18.34, 13.34. HRMS
(ESI): m/z calcd for C24H29F2N4OS




ide (16b). The title compound was prepared from 15b in the same
manner as described for 16a. White solid (yield 92%). HPLC: 99.6%
(λ = 254 nm, tR = 19.6 min).
1H NMR (500 MHz, CDCl3): δ 7.70 (d,
J = 7.3 Hz, 2H), 7.64−7.55 (m, 3H), 6.91−6.82 (m, 2H), 6.68 (d, J =
9.4 Hz, 1H), 4.44 (t, J = 6.1 Hz, 2H), 4.11−4.00 (m, 2H), 3.65 (s,
3H), 3.22−3.07 (m, 4H), 2.34−2.28 (m, 2H), 2.24−2.18 (m, 1H),
1.42 (t, J = 6.8 Hz, 3H), 1.38−1.31 (m, 1H), 1.15−1.09 (m, 1H),
1.08−1.03 (m, 1H). 13C NMR (201 MHz, CD3OD): δ 168.86,
158.50 (d, JCF = 236.7 Hz), 155.05, 152.84, 132.46 (d, JCF = 7.4 Hz),
132.27, 130.20 (2C), 129.84 (2C), 126.92, 113.86 (d, JCF = 22.9 Hz),
113.72 (d, JCF = 24.1 Hz), 113.71, 65.61, 52.96, 46.82, 45.63, 33.66,
26.45, 18.32, 18.30, 15.33, 13.86. HRMS (ESI): m/z calcd for
C24H30FN4OS
+ [M + H]+, 441.2119; found, 441.2112.
N-((2-(5-Fluoro-2-methoxyphenyl)cyclopropyl)methyl)-3-((4-
methyl-5-phenyl-4H-1,2,4-triazol-3-yl)thio)propan-1-amine Hydro-
chloride (16c). The title compound was prepared from 15c in the
same manner as described for 16a. White solid (yield 62%). HPLC:
98.1% (λ = 254 nm, tR = 13.9 min).
1H NMR (500 MHz, CD3OD): δ
7.69 (d, J = 7.3 Hz, 2H), 7.64−7.54 (m, 3H), 6.93−6.86 (m, 2H),
6.71 (d, J = 9.4 Hz, 1H), 4.44 (t, J = 6.6 Hz, 2H), 3.85 (s, 3H), 3.64
(s, 3H), 3.24−3.15 (m, 3H), 3.10−3.01 (m, 1H), 2.37−2.26 (m, 2H),
2.22−2.15 (m, 1H), 1.32−1.23 (m, 1H), 1.18−1.13 (m, 1H), 1.08−
1.01 (m, 1H). 13C NMR (201 MHz, CD3OD): δ 168.85, 158.51 (d,
JCF = 237.0 Hz), 155.84, 152.83, 132.26, 132.09 (d, JCF = 7.5 Hz),
130.19 (2C), 129.83 (2C), 126.91, 114.04 (d, JCF = 24.2 Hz), 113.97
(d, JCF = 23.0 Hz), 112.38 (d, JCF = 9.0 Hz), 56.58, 52.94, 46.85,
45.59, 33.66, 26.45, 18.38, 18.25, 13.29. HRMS (ESI): m/z calcd for
C23H28FN4OS
+ [M + H]+, 427.1962; found, 427.1966.
N-((2-(5-Chloro-2-methoxyphenyl)cyclopropyl)methyl)-3-((4-
methyl-5-phenyl-4H-1,2,4-triazol-3-yl)thio)propan-1-amine (16d).
The title compound was prepared from 15d in the same manner as
described for 16a. Colorless semisolid (yield 58%). 1H NMR (800
MHz, CD3OD): δ 7.70−7.65 (m, 2H), 7.62−7.53 (m, 3H), 7.10 (dd,
J = 8.7, 2.6 Hz, 1H), 6.87 (d, J = 8.7 Hz, 1H), 6.86 (d, J = 2.7 Hz,
1H), 4.41−4.35 (m, 2H), 3.85 (s, 3H), 3.62 (s, 3H), 2.85 (dd, J =
12.4, 6.3 Hz, 1H), 2.79 (t, J = 7.1 Hz, 2H), 2.62 (dd, J = 12.4, 7.8 Hz,
1H), 2.20−2.12 (m, 2H), 2.02−1.98 (m, 1H), 1.20−1.15 (m, 1H),
0.99−0.96 (m, 1H), 0.89−0.85 (m, 1H). HRMS (ESI): m/z calcd for
C23H28ClN4OS
+ [M + H]+, 443.1667; found, 443.1675.
N-((2-(5-Fluoro-2-(2-fluoroethoxy)phenyl)cyclopropyl)methyl)-
N-methyl-3-((4-methyl-5-phenyl-4H-1,2,4-triazol-3-yl)thio)propan-
1-amine Hydrochloride (17a). To a mixture of 16a (40 mg, 0.087
mmol) and formaldehyde solution (37 wt % in water, 0.195 mL, 2.62
mmol) in acetonitrile (8 mL) was added NaHB(AcO)3 (46 mg, 0.22
mmol). The mixture was stirred at room temperature for 1 h. The
reaction was quenched with water and extracted with ethyl acetate.
The organic layers were combined, washed with brine, dried over
Na2SO4, and concentrated. The crude product was purified by flash
chromatography (0−3% methanol in dichloromethane) to give a
colorless oil (24 mg, 58%). The oil was taken up in dichloromethane,
2 M HCl (g) in diethyl ether (2 mL) was added, and the mixture was
stirred at room temperature for 15 min. Volatiles were removed by
evaporation to give the title compound as a white solid. HPLC: 95.7%
(λ = 254 nm, tR = 14.5 min).
1H NMR (500 MHz, CD3OD): δ 7.68
(d, J = 7.1 Hz, 2H), 7.63−7.53 (m, 3H), 6.95−6.84 (m, 2H), 6.71
(dd, J = 9.4, 2.4 Hz, 1H), 4.85−4.67 (m, 2H), 4.40 (s, 2H), 4.33−
4.15 (m, 2H), 3.62 (s, 3H), 3.42−3.22 (m, 4H), 2.97 (s, 3H), 2.41−
2.34 (m, 2H), 2.32−2.23 (m, 1H), 1.35−1.29 (m, 1H), 1.28−1.22
(m, 1H), 1.10−1.03 (m, 1H). 13C NMR (201 MHz, CD3OD): δ
168.89, 158.93 (d, JCF = 237.6 Hz), 154.68, 152.77, 132.54 (d, JCF =
7.5 Hz), 132.27, 130.20 (2C), 129.83 (2C), 126.91, 114.25 (d, JCF =
7.6 Hz), 114.13 (d, JCF = 23.0 Hz), 113.80 (d, JCF = 24.5 Hz), 83.41
(d, JCF = 168.3 Hz), 69.76 (d, JCF = 19.3 Hz), 61.18, 54.41, 46.91,
40.56, 33.63, 24.43, 18.50, 18.42, 17.69. HRMS (ESI): m/z calcd for
C25H31F2N4OS
+ [M + H]+, 473.2181; found, 473.2182.
N-Ethyl-N-((2-(5-fluoro-2-(2-fluoroethoxy)phenyl)cyclopropyl)-
methyl)-3-((4-methyl-5-phenyl-4H-1,2,4-triazol-3-yl)thio)propan-1-
amine Hydrochloride (17b). The title compound was prepared from
16a and acetaldehyde in the same manner as described for 17a. White
solid (yield 42%). HPLC: 97.3% (λ = 254 nm, tR = 14.9 min).
1H
NMR (500 MHz, CD3OD): δ 7.66 (d, J = 6.7 Hz, 2H), 7.63−7.53
(m, 3H), 6.95−6.84 (m, 2H), 6.71 (dd, J = 9.3, 2.4 Hz, 1H), 4.84−
4.66 (m, 2H), 4.40 (s, 2H), 4.32−4.14 (m, 2H), 3.61 (s, 3H), 3.42−
3.32 (m, 6H), 2.40−2.32 (m, 2H), 2.30−2.23 (m, 1H), 1.33 (t, J =
7.2 Hz, 3H), 1.30−1.26 (m, 1H), 1.23−1.20 (m, 1H), 1.10−1.00 (m,
1H). 13C NMR (201 MHz, CD3OD): δ 168.94, 158.92 (d, JCF =
237.9 Hz), 154.71, 152.75, 132.56 (d, JCF = 7.6 Hz), 132.28, 130.21
(2C), 129.79 (2C), 126.90, 114.27 (d, JCF = 8.0 Hz), 114.17 (d, JCF =
23.1 Hz), 113.91 (d, JCF = 24.0 Hz), 83.43 (d, JCF = 168.3 Hz), 69.77
(d, JCF = 19.4 Hz), 57.45, 50.39, 47.00, 33.62, 24.01, 18.45, 17.30,
13.44, 9.20. HRMS (ESI): m/z calcd for C26H33F2N4OS




Hydrochloride (17c). The title compound was prepared from 16b and
formaldehyde in the same manner as described for 17a as a light
yellow solid (yield 72%). HPLC: 96.5% (λ = 254 nm, tR = 16.8 min).
1H NMR (500 MHz, CD3OD): δ 7.68 (d, J = 7.1 Hz, 2H), 7.63−7.54
(m, 3H), 6.91−6.81 (m, 2H), 6.66 (dd, J = 9.5, 2.4 Hz, 1H), 4.41 (t, J
= 5.9 Hz, 2H), 4.12−4.00 (m, 2H), 3.62 (s, 3H), 3.37−3.30 (m, 4H),
2.99 (s, 3H), 2.41−2.34 (m, 2H), 2.32−2.25 (m, 1H), 1.40 (t, J = 7.0
Hz, 3H), 1.35−1.30 (m, 1H), 1.21−1.16 (m, 1H), 1.10−1.02 (m,
1H). 13C NMR (201 MHz, CD3OD): δ 168.60, 158.58 (d, JCF =
236.4 Hz), 154.94 (d, JCF = 2.1 Hz), 152.40, 133.42 (d, JCF = 7.4 Hz),
132.13, 130.15 (2C), 129.77 (2C), 127.00, 113.72 (d, JCF = 8.6 Hz),
113.39 (d, JCF = 22.9 Hz), 112.95 (d, JCF = 24.1 Hz), 65.61, 61.89,
54.60, 47.77, 41.52, 33.57, 25.49, 19.29, 18.20, 15.36, 14.01. HRMS
(ESI): m/z calcd for C25H32FN4OS




drochloride (17d). The title compound was prepared from 16b and
acetaldehyde in the same manner as described for 17a. White solid
(yield 47%). HPLC: 96.4% (λ = 254 nm, tR = 15.2 min).
1H NMR
(500 MHz, CD3OD): δ 7.70−7.53 (m, 5H), 6.91−6.81 (m, 2H), 6.66
(dd, J = 9.4, 2.4 Hz, 1H), 4.41 (t, J = 6.6 Hz, 2H), 4.14−3.98 (m,
2H), 3.62 (s, 3H), 3.43−3.34 (m, 6H), 2.41−2.33 (m, 2H), 2.32−
2.26 (m, 1H), 1.41 (t, J = 6.9 Hz, 3H), 1.35 (t, J = 7.2 Hz, 3H), 1.32−
1.27 (m, 1H), 1.20−1.14 (m, 1H), 1.10−1.03 (m, 1H). 13C NMR
(201 MHz, CD3OD): δ 168.88, 158.53 (d, JCF = 238.4 Hz), 154.99,
152.67, 132.24, 132.19 (d, JCF = 7.8 Hz), 130.19 and 130.18 (2C),
129.81 and 129.77 (2C), 126.90 and 126.84, 113.96 (d, JCF = 22.8
Hz), 113.77 (d, JCF = 7.2 Hz), 113.46 (d, JCF = 25.0 Hz),65.66 and
65.62, 57.41, 50.50 and 50.13, 49.40, 47.07, 33.63, 24.09 and 23.91,
18.55 and 18.35, 17.23 and 17.07, 15.37, 13.92 and 13.73, 9.41, and
9.14. HRMS (ESI): m/z calcd for C26H34FN4OS




amine Hydrochloride (17e). The title compound was prepared from
16c and formaldehyde in the same manner as described for 17a.
White solid (yield 89%). HPLC: 98.9% (λ = 254 nm, tR = 13.7 min).
1H NMR (500 MHz, CD3OD): δ 7.71−7.65 (m, 2H), 7.60 (m, 3H),
6.90 (m, 2H), 6.74−6.67 (m, 1H), 4.43 (m, 2H), 3.85 (s, 3H), 3.63
(s, 3H), 3.49−3.39 (m, 2H), 3.20 (m, 1H), 3.00 (s, 3H), 2.44−2.36
(m, 2H), 2.30−2.24 (m, 1H), 1.31 (m, 2H), 1.25−1.17 (m, 1H), 1.06
(m, 1H). 13C NMR (201 MHz, CD3OD): δ 168.94, 158.56 (d, JCF =
236.6 Hz), 155.77, 152.73, 132.24, 131.79 (d, JCF = 6.9 Hz), 130.17
(2C), 129.80 (2C), 126.89, 114.07 (d, JCF = 22.8 Hz), 113.78 (d, JCF
= 24.3 Hz), 112.51 (d, JCF = 8.3 Hz), 61.17 and 61.03, 56.59, 54.06
and 53.65, 46.93, 40.52 and 40.44, 33.64, 24.37, 18.74 and 18.40,
17.41 and 17.13, 13.45, and 12.85. HRMS (ESI): m/z calcd for
C24H30FN4OS
+ [M + H]+, 441.2119; found, 441.2117.
N-Ethyl-N-((2-(5-fluoro-2-methoxyphenyl)cyclopropyl)methyl)-
3-((4-methyl-5-phenyl-4H-1,2,4-triazol-3-yl)thio)propan-1-amine
Hydrochloride (17f). The title compound was prepared from 16c and
acetaldehyde in the same manner as described for 17a. White solid
(yield 60%). HPLC: 98.0% (λ = 254 nm, tR = 13.9 min).
1H NMR
(500 MHz, CD3OD): δ 7.67−7.53 (m, 5H), 6.93−6.85 (m, 2H), 6.68
(dd, J = 9.6, 2.6 Hz, 1H), 4.46−4.35 (m, 2H), 3.84 (s, 3H), 3.61 (s,
3H), 3.46−3.33 (m, 5H), 3.28−3.19 (m, 1H), 2.37 (p, J = 7.1 Hz,
2H), 2.28−2.18 (m, 1H), 1.35 (t, J = 7.3 Hz, 3H), 1.29−1.22 (m,
1H), 1.20−1.14 (m, 1H), 1.07−1.00 (m, 1H). 13C NMR (201 MHz,
CD3OD): δ 169.01, 158.57 (d, JCF = 237.1 Hz), 155.78, 152.72,
132.25, 131.80 (d, JCF = 6.1 Hz), 130.19 (2C), 129.77 (2C), 126.87,
114.09 (d, JCF = 22.7 Hz), 113.90 (d, JCF = 21.2 Hz), 112.55 (d, JCF =
9.0 Hz), 57.40 and 57.24, 56.63, 50.22 and 50.02, 49.50 and 49.39,
47.01, 33.62, 24.01 and 23.85, 18.63 and 18.51, 17.07, 13.07 and
13.01, 9.31, and 9.19. HRMS (ESI): m/z calcd for C25H32FN4OS
+ [M
+ H]+, 455.2275; found, 455.2270.
N-((2-(5-Fluoro-2-methoxyphenyl)cyclopropyl)methyl)-3-((4-
methyl-5-phenyl-4H-1,2,4-triazol-3-yl)thio)-N-propylpropan-1-
amine Hydrochloride (17g). The title compound was prepared from
16c and propyl aldehyde in the same manner as described for 17a.
White solid (yield 42%). HPLC: 98.2% (λ = 254 nm, tR = 16.0 min).
1H NMR (800 MHz, CD3OD): δ 7.66−7.59 (m, 3H), 7.58−7.54 (m,
2H), 6.91−6.85 (m, 2H), 6.67 (dd, J = 9.4, 2.9 Hz, 1H), 4.44−4.38
(m, 2H), 3.84 and 3.83 (s, 3H), 3.61 and 3.60 (s, 3H), 3.49−3.36 (m,
3H), 3.28−3.18 (m, 3H), 2.43−2.35 (m, 2H), 2.30−2.23 (m, 1H),
1.82−1.72 (m, 2H), 1.29−1.25 (m, 1H), 1.20−1.16 (m, 1H), 1.07−
0.98 (m, 4H). 13C NMR (201 MHz, CD3OD): δ 168.98, 158.57 (d,
JCF = 236.8 Hz), 155.73, 152.70, 132.25, 131.83 (d, JCF = 8.2 Hz),
130.19 (2C), 129.77 (2C), 126.84 (d, JCF = 4.3 Hz), 114.07 (d, JCF =
23.2 Hz), 113.80 (d, JCF = 24.3 Hz), 112.55, 57.90 and 57.84, 56.68
and 56.63, 55.79 and 55.45, 50.82 and 50.55, 47.04, 33.63, 23.95 and
23.79, 18.60, 18.46 and 18.36, 17.15 and 17.06, 13.24 and 13.26,
11.21. HRMS (ESI): m/z calcd for C26H34FN4OS




amine Hydrochloride (17h). The title compound was prepared from
16c and acetone in the same manner as described for 17a. White solid
(yield 24%). HPLC: 97.9% (λ = 254 nm, tR = 14.2 min).
1H NMR
(800 MHz, CD3OD): δ 7.67−7.64 (m, 2H), 7.60−7.54 (m, 3H), 6.83
(dd, J = 8.9, 4.6 Hz, 1H), 6.77 (td, J = 8.5, 3.1 Hz, 1H), 6.54 (dd, J =
9.8, 3.1 Hz, 1H), 4.30−4.23 (m, 2H), 3.81 (s, 3H), 3.61 (s, 3H),
3.18−3.10 (m, 1H), 2.74−2.50 (m, 4H), 2.12−2.01 (m, 3H), 1.13−
1.07 (m, 1H), 1.06−1.01 (m, 6H), 0.93−0.88 (m, 1H), 0.85−0.79
(m, 1H). 13C NMR (201 MHz, CD3OD): δ 168.29, 158.72 (d, J =
237.0 Hz), 155.59, 152.11 (d, JCF = 3.3 Hz), 134.62 (d, JCF = 7.3 Hz),
132.04, 130.14 (2C), 129.75 (2C), 127.14, 112.79 (d, JCF = 23.0 Hz),
112.46 (d, JCF = 23.9 Hz), 112.38 (d, JCF = 6.5 Hz), 56.67, 55.40,
51.87, 48.59, 47.70, 33.50, 27.71, 22.74, 18.78, 17.97, 17.87, 14.51.
HRMS (ESI): m/z calcd for C26H34FN4OS




thio)propan-1-amine Hydrochloride (17i). The title compound was
prepared from 16c and cyclopropanecarbaldehyde in the same
manner as described for 17a. White solid (yield 68%). HPLC:
98.8% (λ = 254 nm, tR = 14.6 min).
1H NMR (800 MHz, CD3OD): δ
7.66−7.63 (m, 2H), 7.62−7.59 (m, 1H), 7.58−7.55 (m, 2H), 6.92−
6.85 (m, 2H), 6.68 (dd, J = 9.4, 2.3 Hz, 1H), 4.43 and 4.41 (t, J = 6.4
Hz, 2H), 3.84 (s, 3H), 3.62 and 3.60 (s, 3H), 3.53−3.42 (m, 3H),
3.34−3.24 (m, 2H), 3.19−3.15 (m, 1H), 2.41−2.34 (m, 2H), 2.30−
2.24 (m, 1H), 1.31−1.26 (m, 1H), 1.21−1.18 (m, 1H), 1.18−1.11
(m, 1H), 1.09−1.02 (m, 1H), 0.79−0.72 (m, 2H), 0.48−0.39 (m,
2H). 13C NMR (201 MHz, CD3OD): δ 168.98 and 168.91, 158.55
(d, JCF = 236.9 Hz), 155.72, 152.64, 132.24, 131.87 (d, JCF = 7.3 Hz),
130.18 (2C), 129.75 (2C), 126.84 (d, JCF = 6.1 Hz), 114.04 (d, JCF =
22.7 Hz), 113.78 and 113.68 (d, JCF = 24.0 Hz), 112.52 (d, JCF = 9.4
Hz), 59.21 and 58.86, 57.78 and 57.75, 56.69 and 56.65, 50.80 and
50.43, 47.11, 33.64, 24.12 and 23.94, 18.63 and 18.53, 17.20 and
17.14, 13.24 and 13.22, 6.71 and 6.63, 5.26 and 5.11, 5.08, and 4.91.
HRMS (ESI): m/z calcd for C27H34FN4OS




Hydrochloride (17j). The title compound was prepared from 16d and
acetaldehyde in the same manner as described for 17a. White solid
(yield 58%). HPLC: 97.8% (λ = 254 nm, tR = 14.8 min).
1H NMR
(800 MHz, CD3OD): δ 7.64−7.59 (m, 3H), 7.58−7.54 (m, 2H), 7.15
(t, J = 7.0 Hz, 1H), 6.92−6.90 (m, 2H), 4.47−4.37 (m, 2H), 3.85 (s,
3H), 3.60 and 3.59 (s, 3H), 3.46−3.34 (m, 5H), 3.28−3.21 (m, 1H),
2.40−2.34 (m, 2H), 2.25−2.17 (m, 1H), 1.35 (t, J = 7.3 Hz, 3H),
1.27−1.21 (m, 1H), 1.19−1.15 (m, 1H), 1.05−0.99 (m, 1H). 13C
NMR (201 MHz, CD3OD): δ 158.31, 152.74, 132.27, 131.83, 130.20
(2C), 129.73 (2C), 128.28, 127.22, 127.08, 126.82, 126.63, 112.88,
57.40 and 57.21, 56.42 and 56.39, 50.11 and 49.97, 46.96 and 46.94,
33.62, 28.10, 23.94 and 23.80, 18.55 and 18.39, 16.93 and 16.81,
12.85 and 12.76, 9.27, and 9.18. HRMS (ESI): m/z calcd for
C25H32ClN4OS
+ [M + H]+, 471.1980; found, 471.1977.
N-((2-(5-Chloro-2-methoxyphenyl)cyclopropyl)methyl)-3-((4-
methyl-5-phenyl-4H-1,2,4-triazol-3-yl)thio)-N-propylpropan-1-
amine Hydrochloride (17k). The title compound was prepared from
16d and propyl aldehyde in the same manner as described for 17a.
White solid (yield 85%). HPLC: 95.6% (λ = 254 nm, tR = 15.1 min).
1H NMR (800 MHz, CD3OD): δ 7.64−7.58 (m, 3H), 7.57−7.53 (m,
2H), 7.14 (t, J = 7.0 Hz, 1H), 6.92−6.87 (m, 2H), 4.45−4.36 (m,
2H), 3.84 (s, 3H), 3.60 and 3.59 (s, 3H), 3.48−3.35 (m, 3H), 3.27−
3.17 (m, 3H), 2.41−2.33 (m, 2H), 2.24−2.17 (m, 1H), 1.81−1.71
(m, 2H), 1.27−1.22 (m, 1H), 1.18−1.14 (m, 1H), 1.05−0.98 (m,
4H). 13C NMR (201 MHz, CD3OD): δ 158.28, 152.71, 132.26,
131.84, 130.20 (2C), 129.72 (2C), 128.24, 127.14, 126.99, 126.82,
126.64, 112.88, 57.87 and 57.76, 56.42 and 56.40, 55.78 and 55.51,
50.68 and 50.49, 46.96, 33.62, 23.89 and 23.74, 18.51 and 18.45,
18.37 and 18.33, 16.95 and 16.80, 12.98 and 12.91, 11.16. HRMS
(ESI): m/z calcd for C26H34ClN4OS




propan-1-amine Hydrochloride (17l). The title compound was
prepared from 16d and cyclopropanecarbaldehyde in the same
manner as described for 17a. White solid (yield 77%). HPLC: 99.3%
(λ = 254 nm, tR = 15.2 min).
1H NMR (800 MHz, CD3OD): δ 7.66−
7.56 (m, 5H), 7.19−7.14 (m, 1H), 6.95−6.90 (m, 2H), 4.46−4.40
(m, 2H), 3.86 (s, 3H), 3.62 and 3.60 (s, 3H), 3.55−3.49 (m, 2H),
3.49−3.39 (m, 1H), 3.35−3.30 (m, 1H), 3.30−3.24 (m, 1H), 3.20−
3.15 (m, 1H), 2.43−2.35 (m, 2H), 2.28−2.20 (m, 1H), 1.29−1.24
(m, 1H), 1.22−1.17 (m, 1H), 1.17−1.13 (m, 1H), 1.08−1.02 (m,
1H), 0.80−0.73 (m, 2H), 0.48−0.41 (m, 2H). 13C NMR (201 MHz,
CD3OD): δ 158.29, 152.72, 132.28, 131.80, 130.22 (2C), 129.72
(2C), 128.24, 127.13, 126.97, 126.80, 126.64, 112.89, 59.25 and
58.95, 57.72, 56.41, 50.69 and 50.38, 47.03, 33.63, 24.05 and 23.88,
18.53 and 18.40, 16.93, 12.94, 6.68 and 6.62, 5.15 and 5.10, 5.01, and
4.84. HRMS (ESI): m/z calcd for C27H34ClN4OS
+ [M + H]+,
497.2136; found, 497.2133.
N-(4-Hydroxybutyl)-2-naphthamide (19a). 2-Naphthoyl chloride
(218 mg, 1.14 mmol) was dissolved in dichloromethane (10 mL), and
then trimethylamine (174 mg, 1.72 mmol) and 4-aminobutanol (112
mg, 1.26 mmol) were added successively. The mixture was stirred at
room temperature for 2 h. The solvent was evaporated under a
vacuum to give a residue, which was then taken up in ethyl acetate
and washed with saturated aqueous NaHCO3 and then brine. The
organic layer was separated and concentrated to give the crude
product, which was purified by flash chromatography (0−5%
methanol in dichloromethane) to give the title compound as a
white solid (243 mg, 87%). 1H NMR (800 MHz, CDCl3): δ 8.30 (s,
1H), 7.93 (d, J = 8.0 Hz, 1H), 7.90 (d, J = 8.5 Hz, 1H), 7.88 (d, J =
8.0 Hz, 1H), 7.84 (dd, J = 8.5, 1.6 Hz, 1H), 7.59−7.53 (m, 2H), 3.77
(t, J = 6.1 Hz, 2H), 3.59 (t, J = 6.9 Hz, 2H), 1.82−1.77 (m, 2H),
1.75−1.71 (m, 2H). HRMS (ESI): m/z calcd for C15H18NO2+ [M +
H]+, 244.1332; found, 244.1329.
N-(4-Hydroxybutyl)-1H-indole-2-carboxamide (19b). A mixture
of 1H-indole-2-carboxylic acid (200 mg, 1.24 mmol), 4-aminobutanol
(132 mg, 1.49 mmol), HATU (708 mg, 1.88 mmol), and NaHCO3
(313 mg, 3.72 mmol) in DMF (10 mL) was stirred at room
temperature for 2 h. The mixture was diluted with ethyl acetate,
washed with water, and then brine. The organic layer was separated
and concentrated to give a crude product, which was purified by flash
chromatography (0−5% methanol in dichloromethane) to give the
title compound as a white solid (231 mg, 80%). 1H NMR (800 MHz,
CD3OD): δ 7.61 (d, J = 8.0 Hz, 1H), 7.45 (dd, J = 8.3, 0.7 Hz, 1H),
7.24−7.20 (m, 1H), 7.08−7.05 (m, 2H), 3.63 (t, J = 6.5 Hz, 2H),
3.44 (t, J = 7.1 Hz, 2H), 1.75−1.69 (m, 2H), 1.68−1.63 (m, 2H).
HRMS (ESI): m/z calcd for C13H17N2O2
+ [M + H]+, 233.1285;
found, 233.1280.
N-(4-Hydroxybutyl)-4-(pyridin-2-yl)benzamide (19c). The title
compound was prepared from 4-(pyridin-2-yl)benzoic acid using
the same method as described for compound 19b. White solid (yield
93%). 1H NMR (800 MHz, CD3OD): δ 8.66 (d, J = 4.8 Hz, 1H),
8.07 (d, J = 8.3 Hz, 2H), 7.96−7.92 (m, 4H), 7.44−7.40 (m, 1H),
3.63 (t, J = 6.5 Hz, 2H), 3.45 (t, J = 7.1 Hz, 2H), 1.76−1.70 (m, 2H),
1.68−1.61 (m, 2H). HRMS (ESI): m/z calcd for C16H19N2O2+ [M +
H]+, 271.1441; found, 271.1434.
General Procedures for the Preparation of 20a−c. A mixture
of the SO3−pyridine complex (5.0 equiv) in dichloromethane (0.25
mol/L) and DMSO (0.25 mol/L) was cooled to 0 °C. Then a mixture
of amides 19a−c (1.0 equiv) and trimethylamine (5.0 equiv) in
DMSO (0.12 mol/L) was added dropwise. The mixture was stirred at
room temperature for 1.5 h. Water was added, and the mixture was
extracted with ethyl acetate. The combined extracts were washed with
brine, dried over Na2SO4, and concentrated to give an oil, which was
used in the next step without further purification.
N-((2-(5-Fluoro-2-methoxyphenyl)cyclopropyl)methyl)-
ethanamine (21a). A mixture of 14c (162 mg, 0.70 mmol),
acetaldehyde (31 mg, 0.70 mmol), and trimethylamine (71 mg,
0.70 mmol) in THF (20 mL) was stirred at room temperature for 1 h.
NaBH4 (79 mg, 2.10 mmol) was then added, and the reaction mixture
was stirred at room temperature for 20 min. MeOH (5 mL) was
added to quench the reaction. Water was added, and the mixture was
extracted with ethyl acetate. The combined extracts were washed with
brine and concentrated. The residue was purified by flash
chromatography (0−8% methanol in dichloromethane) to give the
title compound as a yellow oil (53 mg, 34%). 1H NMR (800 MHz,
CD3OD): δ 6.92−6.87 (m, 2H), 6.71 (dd, J = 9.4, 3.0 Hz, 1H), 3.85
(s, 3H), 3.12−2.94 (m, 4H), 2.16−2.13 (m, 1H), 1.31 (t, J = 7.3 Hz,
3H), 1.28−1.22 (m, 1H), 1.14−1.11 (m, 1H), 1.03−0.99 (m, 1H).
HRMS (ESI): m/z calcd for C13H19FNO
+ [M + H]+, 224.1445;
found, 224.1453.
N-((2-(5-Chloro-2-methoxyphenyl)cyclopropyl)methyl)-
ethanamine (21b). Using a similar method as described for 21a, the
title compound was prepared as a brown oil (yield 33%). 1H NMR
(800 MHz, CD3OD): δ 7.17 (dd, J = 8.7, 2.5 Hz, 1H), 6.96 (d, J = 2.6
Hz, 1H), 6.93 (d, J = 8.7 Hz, 1H), 3.87 (s, 3H), 3.16−3.08 (m, 3H),
3.03 (dd, J = 13.3, 8.3 Hz, 1H), 2.18−2.11 (m, 1H), 1.35 (t, J = 7.3
Hz, 3H), 1.30−1.23 (m, 1H), 1.18−1.12 (m, 1H), 1.07−1.00 (m,
1H). HRMS (ESI): m/z calcd for C13H19ClNO
+ [M + H]+, 240.1150;
found, 240.1156.
N-((2-(5-Fluoro-2-methoxyphenyl)cyclopropyl)methyl)propan-1-
amine (21c). Using a similar method as described for 21a, the title
compound was prepared as a colorless oil (yield 23%). 1H NMR (800
MHz, CD3OD): δ 6.89 (dd, J = 8.9, 4.6 Hz, 1H), 6.87−6.84 (m, 1H),
6.67 (dd, J = 9.5, 3.0 Hz, 1H), 3.84 (s, 3H), 2.93 (dd, J = 12.5, 6.5 Hz,
1H), 2.82−2.76 (m, 2H), 2.73 (dd, J = 12.5, 7.8 Hz, 1H), 2.07−2.03
(m, 1H), 1.67−1.60 (m, 2H), 1.22−1.16 (m, 1H), 1.08−1.04 (m,
1H), 0.99 (t, J = 7.4 Hz, 3H), 0.95−0.91 (m, 1H). HRMS (ESI): m/z
calcd for C14H21FNO
+ [M + H]+, 238.1602; found, 238.1603.
N-((2-(5-Chloro-2-methoxyphenyl)cyclopropyl)methyl)propan-
1-amine (21d). Using a similar method as described for 21a, the title
compound was prepared as a colorless oil (yield 31%). 1H NMR (800
MHz, CD3OD): δ 7.16 (dd, J = 8.7, 2.6 Hz, 1H), 6.95 (d, J = 2.6 Hz,
1H), 6.93 (d, J = 8.7 Hz, 1H), 3.86 (s, 3H), 3.13 (dd, J = 12.9, 7.1 Hz,
1H), 3.05−2.96 (m, 3H), 2.17−2.13 (m, 1H), 1.77−1.71 (m, 2H),
1.31−1.24 (m, 1H), 1.17−1.12 (m, 1H), 1.06−1.01 (m, 4H). HRMS
(ESI): m/z calcd for C14H21ClNO
+ [M + H]+, 254.1306; found,
254.1310.
General Procedures for the Preparation of 22a−i. To a
solution of amines 21a−d (1.0 equiv) in THF was added aldehydes
20a−c (1.0 equiv) and NaHB(AcO)3 (2.0 equiv), and the reaction
mixture was stirred at room temperature overnight. Methanol was
added to afford a clear solution, which was stirred at room
temperature for 15−30 min. The solution was concentrated, and
the residue was purified by flash chromatography (0−6% methanol in
dichloromethane) to give a colorless oil (22a−i free bases). These
free bases were converted into their HCl salts using 2 M HCl (g) in
diethyl ether in the same manner as described for 17a.
N-(4-(Ethyl((2-(5-fluoro-2-methoxyphenyl)cyclopropyl)methyl)-
amino)butyl)-2-naphthamide Hydrochloride (22a). White solid
(yield 37%). HPLC: 99.3% (λ = 254 nm, tR = 15.4 min).
1H NMR
(800 MHz, CD3OD): δ 8.38 (d, J = 7.6 Hz, 1H), 7.97 (t, J = 8.1 Hz,
1H), 7.95−7.91 (m, 2H), 7.91−7.87 (m, 1H), 7.61−7.56 (m, 2H),
6.91−6.85 (m, 2H), 6.71−6.69 (m, 1H), 3.83 and 3.82 (s, 3H), 3.54−
3.48 (m, 2H), 3.42−3.32 (m, 4H), 3.30−3.21 (m, 2H), 2.32−2.28
(m, 1H), 1.90−1.80 (m, 2H), 1.79−1.71 (m, 2H), 1.38−1.35 (m,
3H), 1.34−1.29 (m, 1H), 1.24−1.19 (m, 1H), 1.08−1.04 (m, 1H).
13C NMR (201 MHz, CD3OD): δ 170.38, 158.66 (d, JCF = 237.0 Hz),
155.70, 136.29, 134.05, 132.71, 131.95 (d, JCF = 7.1 Hz), 130.00,
129.39, 128.91, 128.78 (2C), 127.91, 124.80, 113.96 (d, JCF = 22.9
Hz), 113.42 and 113.40 (d, JCF = 24.1 Hz), 112.55 (d, JCF = 8.6 Hz),
57.53 and 57.43, 56.56, 55.34 and 55.06, 53.23 and 52.96, 39.94 and
39.91, 27.83, 22.49 and 22.34, 18.44, 17.46 and 17.39, 13.36 and
13.19, 9.31, and 9.10. HRMS (ESI): m/z calcd for C28H34FN2O2
+ [M
+ H]+, 449.2599; found, 449.2604.
N-(4-(((2-(5-Fluoro-2-methoxyphenyl)cyclopropyl)methyl)-
(propyl)amino)butyl)-2-naphthamide Hydrochloride (22b). White
solid (yield 68%). HPLC: 99.4% (λ = 254 nm, tR = 21.7 min).
1H
NMR (800 MHz, CD3OD): δ 8.39 (d, J = 7.4 Hz, 1H), 7.97 (t, J =
7.6 Hz, 1H), 7.95−7.88 (m, 3H), 7.62−7.53 (m, 2H), 6.92−6.84 (m,
2H), 6.71−6.66 (m, 1H), 3.82 (s, 3H), 3.54−3.48 (m, 2H), 3.40−
3.28 (m, 3H), 3.28−3.16 (m, 3H), 2.32−2.27 (m, 1H), 1.90−1.82
(m, 2H), 1.81−1.72 (m, 4H), 1.36−1.32 (m, 1H), 1.23−1.19 (m,
1H), 1.09−1.04 (m, 1H), 1.02−0.97 (m, 3H). 13C NMR (201 MHz,
CD3OD): δ 170.36, 158.68 (d, JCF = 236.7 Hz), 155.66 (d, JCF = 2.8
Hz), 136.29, 134.05, 132.71, 131.97 (d, JCF = 7.4 Hz), 130.00, 129.39,
128.91, 128.79 (2C), 127.91, 124.80, 114.00, and 113.89 (d, JCF =
22.9 Hz), 113.37 and 113.25 (d, JCF = 24.2 Hz), 112.58 and 112.54
(d, JCF = 8.5 Hz), 58.07, 56.58, 55.76 and 55.34, 53.90 and 53.52,
39.91 and 39.88, 27.81, 22.42 and 22.27, 18.46 and 18.31, 18.41,
17.52 and 17.45, 13.44, 11.22, and 11.21. HRMS (ESI): m/z calcd for
C29H36FN2O2
+ [M + H]+, 463.2755; found, 463.2764.
N-(4-(Ethyl((2-(5-fluoro-2-methoxyphenyl)cyclopropyl)methyl)-
amino)butyl)-H-indole-2-carboxamide Hydrochloride (22c). White
solid (yield 44%). HPLC: 98.9% (λ = 280 nm, tR = 14.0 min).
1H
NMR (800 MHz, CD3OD): δ 7.60 (d, J = 8.0 Hz, 1H), 7.44 (d, J =
8.3 Hz, 1H), 7.23−7.19 (m, 1H), 7.07−7.04 (m, 2H), 6.91−6.85 (m,
2H), 6.69 (dd, J = 9.5, 2.9 Hz, 1H), 3.82 (s, 3H), 3.46 (t, J = 6.8 Hz,
2H), 3.37−3.20 (m, 6H), 2.30−2.26 (m, 1H), 1.84−1.76 (m, 2H),
1.75−1.69 (m, 2H), 1.34 (t, J = 7.3 Hz, 3H), 1.30−1.26 (m, 1H),
1.23−1.20 (m, 1H), 1.06−1.01 (m, 1H). 13C NMR (201 MHz,
CD3OD): δ 164.33, 158.63 (d, JCF = 236.7 Hz), 155.69, 138.29,
132.09, 131.95 (d, JCF = 7.3 Hz), 128.96, 125.11, 122.75, 121.22,
113.94 (d, JCF = 22.8 Hz), 113.40 (d, JCF = 24.3 Hz), 113.07, 112.54
(d, JCF = 7.2 Hz), 104.51, 57.50 and 57.41, 56.56, 53.19 and 52.91,
48.62, 39.40, 27.88, 22.45 and 22.31, 18.43 and 18.42, 17.46 and
17.40, 13.34 and 13.15, 9.30, and 9.09. HRMS (ESI): m/z calcd for
C26H33FN3O2
+ [M + H]+, 438.2551; found, 438.2550.
N-(4-(((2-(5-Fluoro-2-methoxyphenyl)cyclopropyl)methyl)-
(propyl)amino)butyl)-1H-indole-2-carboxamide Hydrochloride
(22d). White solid (yield 65%). HPLC: 98.5% (λ = 280 nm, tR =
14.7 min). 1H NMR (800 MHz, CD3OD): δ 7.61−7.58 (m, 1H),
7.45−7.43 (m, 1H), 7.23−7.19 (m, 1H), 7.09−7.05 (m, 2H), 6.91−
6.85 (m, 2H), 6.70−6.67 (m, 1H), 3.82 (s, 3H), 3.49−3.44 (m, 2H),
3.35−3.25 (m, 3H), 3.25−3.14 (m, 3H), 2.31−2.26 (m, 1H), 1.86−
1.69 (m, 6H), 1.34−1.28 (m, 1H), 1.23−1.19 (m, 1H), 1.07−1.03
(m, 1H), 1.03−0.97 (m, 3H). 13C NMR (201 MHz, CD3OD): δ
164.33, 158.65 (d, JCF = 236.8 Hz), 155.65, 138.30, 132.08, 131.96 (d,
JCF = 7.6 Hz), 128.96, 125.12, 122.75, 121.23, 113.93, and 113.92 (d,
JCF = 23.3 Hz), 113.31 and 113.28 (d, JCF = 24.3 Hz), 113.08, 112.56,
and 112.54 (d, JCF = 7.5 Hz), 104.51, 58.05, 56.58, 55.71 and 55.30,
53.86 and 53.48, 39.38, 27.85, 22.38 and 22.27, 18.44 and 18.39,
18.29, 17.52 and 17.45, 13.41 and 13.39, 11.20. HRMS (ESI): m/z
calcd for C27H35FN3O2
+ [M + H]+, 452.2708; found, 452.2714.
N-(4-(((2-(5-Fluoro-2-methoxyphenyl)cyclopropyl)methyl)-
(propyl)amino)butyl)-4-(pyridin-2-yl)benzamide Hydrochloride
(22e). White solid (yield 57%). HPLC: 98.5% (λ = 254 nm, tR =
13.6 min). 1H NMR (800 MHz, CD3OD): δ 8.90 (d, J = 5.6 Hz, 1H),
8.71 (t, J = 8.1 Hz, 1H), 8.45 (d, J = 8.2 Hz, 1H), 8.17−8.13 (m, 2H),
8.11−8.06 (m, 3H), 6.93−6.91 (m, 1H), 6.89−6.86 (m, 1H), 6.72−
6.69 (m, 1H), 3.85 (s, 3H), 3.52−3.47 (m, 2H), 3.40−3.32 (m, 2H),
3.31−3.18 (m, 4H), 2.34−2.30 (m, 1H), 1.91−1.84 (m, 2H), 1.82−
1.72 (m, 4H), 1.40−1.34 (m, 1H), 1.25−1.20 (m, 1H), 1.11−1.07
(m, 1H), 1.05−1.00 (m, 3H). 13C NMR (201 MHz, CD3OD): δ
168.77, 158.68 (d, JCF = 237.2 Hz), 155.69, 153.21 (d, JCF = 4.2 Hz),
148.23, 143.61, 138.88, 135.19, 132.04 (d, JCF = 7.3 Hz), 129.73
(2C), 129.60 (2C), 127.56, 127.19, 113.93 (d, JCF = 22.9 Hz), 113.30
(d, JCF = 24.5 Hz), 112.60 (d, JCF = 8.2 Hz), 58.06, 56.62, 55.79 and
55.35, 53.88 and 53.49, 40.10 and 40.07, 27.67, 22.50 and 22.37,
18.48 and 18.32, 18.43 and 18.41, 17.54 and 17.45, 13.50, 11.26, and
11.24. HRMS (ESI): m/z calcd for C30H37FN3O2
+ [M + H]+,
490.2864; found, 490.2863.
N-(4-(((2-(5-Chloro-2-methoxyphenyl)cyclopropyl)methyl)-
(ethyl)amino)butyl)-2-naphthamide Hydrochloride (22f). White
solid (yield 86%). HPLC: 98.8% (λ = 254 nm, tR = 17.5 min).
1H
NMR (600 MHz, CD3OD): δ 8.37 (d, J = 3.9 Hz, 1H), 7.99−7.91
(m, 3H), 7.89−7.85 (m, 1H), 7.62−7.54 (m, 2H), 7.15 (dd, J = 8.7,
2.6 Hz, 1H), 6.95−6.86 (m, 2H), 3.84 and 3.83 (s, 3H), 3.53−3.49
(m, 2H), 3.42−3.32 (m, 4H), 3.29−3.22 (m, 2H), 2.29−2.24 (m,
1H), 1.88−1.80 (m, 2H), 1.79−1.72 (m, 2H), 1.35 (t, J = 7.2 Hz,
3H), 1.33−1.29 (m, 1H), 1.26−1.20 (m, 1H), 1.08−1.02 (m, 1H).
13C NMR (201 MHz, CD3OD): δ 170.40, 158.23, 136.28, 134.04,
132.71, 131.95, 129.98, 129.39, 128.91, 128.79, 128.74, 128.11,
127.92, 126.67, 126.65, 124.76, 112.83, 57.52 and 57.44, 56.31(2C),
53.18 and 52.93, 39.93 and 39.89, 27.84, 22.44 and 22.27, 18.29,
17.23 and 17.17, 13.21 and 13.07, 9.25, and 9.06. HRMS (ESI): m/z
calcd for C28H34ClN2O2
+ [M + H]+, 465.2303; found, 465.2309.
N-(4-(((2-(5-Chloro-2-methoxyphenyl)cyclopropyl)methyl)-
(propyl)amino)butyl)-2-naphthamide Hydrochloride (22g). Color-
less oil (yield 63%). HPLC: 95.4% (λ = 280 nm, tR = 24.7 min).
1H
NMR (800 MHz, CD3OD): δ 8.38 (d, J = 5.8 Hz, 1H), 7.99−7.93
(m, 3H), 7.91−7.88 (m, 1H), 7.62−7.57 (m, 2H), 7.15 (dd, J = 8.7,
2.6 Hz, 1H), 6.94−6.91 (m, 2H), 3.85 and 3.84 (s, 3H), 3.55−3.50
(m, 2H), 3.40−3.33 (m, 2H), 3.30−3.17 (m, 4H), 2.29−2.26 (m,
1H), 1.88−1.81 (m, 2H), 1.81−1.73 (m, 4H), 1.37−1.32 (m, 1H),
1.26−1.21 (m, 1H), 1.09−1.05 (m, 1H), 1.04−1.00 (m, 3H). 13C
NMR (201 MHz, CD3OD): δ 170.37, 158.19, 136.27, 134.03, 132.71,
131.98, 129.98, 129.39, 128.90, 128.78, 128.75, 128.07, 127.91,
126.69, 126.58 and 126.55, 124.77, 112.83, 58.03, 56.31, 55.71 and
55.35, 53.81 and 53.46, 39.88, 27.80, 22.36 and 22.20, 18.42 and
18.28, 18.28 and 18.24, 17.26 and 17.20, 13.31 and 13.29, 11.18.
HRMS (ESI): m/z calcd for C29H36ClN2O2




(22h). White solid (yield 49%). HPLC: 97.2% (λ = 280 nm, tR =
12.6 min). 1H NMR (800 MHz, CD3OD): δ 7.60 (d, J = 8.0 Hz, 1H),
7.45 (d, J = 9.0 Hz, 1H), 7.21 (t, J = 7.6 Hz, 1H), 7.13 (dd, J = 8.7,
2.5 Hz, 1H), 7.10−7.08 (m, 1H), 7.06 (t, J = 7.5 Hz, 1H), 6.91−6.90
(m, 1H), 6.89 (d, J = 8.7 Hz, 1H), 3.82 (s, 3H), 3.49−3.44 (m, 2H),
3.35−3.13 (m, 6H), 2.28−2.22 (m, 1H), 1.87−1.80 (m, 2H), 1.79−
1.68 (m, 4H), 1.35−1.30 (m, 1H), 1.23−1.19 (m, 1H), 1.07−1.03
(m, 1H), 1.01−0.96 (m, 3H). 13C NMR (201 MHz, CD3OD): δ
164.36, 158.20 and 158.19, 138.31, 132.07, 132.00, 128.97, 128.08,
126.69, 126.57 and 126.55, 125.11, 122.75, 121.23, 113.07, 112.85
and 112.84, 104.45, 58.07, 56.34, 55.73 and 55.35, 53.86 and 53.51,
39.37, 27.88, 22.38 and 22.26, 18.45 and 18.31, 18.27, 17.33 and
17.27, 13.31, 11.21, and 11.20. HRMS (ESI): m/z calcd for
C27H35ClN3O2
+ [M + H]+, 468.2412; found, 468.2410.
N-(4-(((2-(5-Chloro-2-methoxyphenyl)cyclopropyl)methyl)-
(propyl)amino)butyl)-4-(pyridin-2-yl)benzamide Hydrochloride
(22i). White solid (yield 64%). HPLC: 98.5% (λ = 254 nm, tR =
15.3 min). 1H NMR (800 MHz, CD3OD): δ 8.87 (d, J = 5.5 Hz, 1H),
8.69 (t, J = 7.9 Hz, 1H), 8.42 (d, J = 8.1 Hz, 1H), 8.13−8.10 (m, 2H),
8.09−8.04 (m, 3H), 7.15−7.13(m, 1H), 6.93−6.91 (m, 2H), 3.85 (s,
3H), 3.52−3.48 (m, 2H), 3.39−3.14 (m, 5H), 3.08−2.98 (m, 1H),
2.30−2.25 (m, 1H), 1.89−1.72 (m, 6H), 1.37−1.31 (m, 1H), 1.24−
1.21 (m, 1H), 1.09−1.06 (m, 1H), 1.05−0.99 (m, 3H). 13C NMR
(201 MHz, CD3OD): δ 168.82, 158.25, 148.24, 143.57, 138.83,
132.06, 129.66 (2C), 129.59 (2C), 128.12, 128.07, 127.58, 127.25,
127.18, 126.66 and 126.61, 126.57, 112.90 and 112.89, 58.11, 56.38,
55.77 and 55.40, 53.86 and 53.51, 40.11 and 40.08, 27.6, 22.44 and
22.29, 18.47 and 18.33, 18.30 and 18.27, 17.40 and 17.31, 13.29,
11.19. HRMS (ESI): m/z calcd for C30H37ClN3O2
+ [M + H]+,
506.2569; found, 506.2566.
General Procedures for the Preparation of 24a−f. To a
solution of benzaldehydes 23a−f (1.0 equiv) in anhydrous dichloro-
m e t h a n e ( 0 . 1− 0 . 2 m o l / L ) w a s a d d e d m e t h y l
(triphenylphosphoranylidene)acetate (1.3 equiv), and the solution
was stirred at room temperature overnight. The mixture was then
concentrated, and the residue was purified by flash chromatography
(0−15% ethyl acetate in petroleum ether) to give intermediates 24a−
f.
Methyl (E)-3-(3-fluorophenyl)acrylate (24a). Colorless oil (yield
67%). 1H NMR (600 MHz, CDCl3): δ 7.67 (d, J = 16.0 Hz, 1H),
7.41−7.35 (m, 1H), 7.31 (d, J = 7.7 Hz, 1H), 7.24 (d, J = 9.7 Hz,
1H), 7.11 (td, J = 8.3, 1.9 Hz, 1H), 6.46 (d, J = 16.0 Hz, 1H), 3.84 (s,
3H). HRMS (ESI): m/z calcd for C10H10FO2
+ [M + H]+, 181.0659;
found, 181.0657.
Methyl (E)-3-(3-chlorophenyl)acrylate (24b). White solid (yield
96%). 1H NMR (800 MHz, CDCl3): δ 7.62 (d, J = 16.0 Hz, 1H), 7.50
(t, J = 1.7 Hz, 1H), 7.39 (d, J = 7.5 Hz, 1H), 7.37−7.34 (m, 1H), 7.32
(t, J = 7.7 Hz, 1H), 6.43 (d, J = 16.0 Hz, 1H), 3.81 (s, 3H). HRMS
(ESI): m/z calcd for C10H10ClO2
+ [M + H]+, 197.0364; found,
197.0356.
Methyl (E)-3-(4-fluorophenyl)acrylate (24c). White solid (yield
93%). 1H NMR (800 MHz, CDCl3): δ 7.65 (d, J = 16.0 Hz, 1H),
7.52−7.50 (m, 2H), 7.09−7.05 (m, 2H), 6.36 (d, J = 16.0 Hz, 1H),
3.80 (s, 3H). HRMS (ESI): m/z calcd for C10H10FO2
+ [M + H]+,
181.0659; found, 181.0653.
Methyl (E)-3-(4-chlorophenyl)acrylate (24d). White solid (yield
89%). 1H NMR (800 MHz, CDCl3): δ 7.63 (d, J = 16.0 Hz, 1H), 7.44
(d, J = 8.3 Hz, 2H), 7.35 (d, J = 8.3 Hz, 2H), 6.40 (d, J = 16.0 Hz,
1H), 3.80 (s, 3H). HRMS (ESI): m/z calcd for C10H10ClO2
+ [M +
H]+, 197.0364; found, 197.0359.
Methyl (E)-3-(4-(trifluoromethyl)phenyl)acrylate (24e). White
solid (yield 97%). 1H NMR (800 MHz, CDCl3): δ 7.70 (d, J =
16.0 Hz, 1H), 7.65 (d, J = 8.4 Hz, 2H), 7.62 (d, J = 8.4 Hz, 2H), 6.51
(d, J = 16.0 Hz, 1H), 3.83 (s, 3H). HRMS (ESI): m/z calcd for
C11H10F3O2
+ [M + H]+, 231.0627; found, 231.0625.
Methyl (E)-3-(2,3-dichlorophenyl)acrylate (24f). White solid
(yield 98%). 1H NMR (800 MHz, CDCl3): δ 8.09 (d, J = 16.0 Hz,
1H), 7.51 (dd, J = 7.8, 1.3 Hz, 1H), 7.49 (dd, J = 8.0, 1.5 Hz, 1H),
7.23 (t, J = 7.9 Hz, 1H), 6.41 (d, J = 16.0 Hz, 1H), 3.83 (s, 3H).
HRMS (ESI): m/z calcd for C11H9Cl2O2
+ [M + H]+, 230.9974;
found, 230.9970.
General Method for the Preparation of 25a−f. To a solution
of esters 24a−f (1.0 equiv) in THF/H2O (v/v = 5/2, 0.1 mol/L) was
added LiOH−H2O (5.0 equiv), and the solution was stirred at room
temperature for 2 h. Water was added, and 4 M HCl (aq) was added
to adjust the pH to 5. The mixture was extracted with ethyl acetate,
washed with brine, dried over Na2SO4, and concentrated to give acid
intermediates 25a−f as white solids.
(E)-3-(3-Fluorophenyl)acrylic acid (25a). White solid (yield 75%).
1H NMR (800 MHz, CDCl3): δ 7.75 (d, J = 15.9 Hz, 1H), 7.40−7.37
(m, 1H), 7.33 (d, J = 7.7 Hz, 1H), 7.26−7.24 (m, 1H), 7.12 (td, J =
8.2, 1.9 Hz, 1H), 6.45 (d, J = 16.0 Hz, 1H).
(E)-3-(3-Chlorophenyl)acrylic acid (25b). White solid (yield
100%). 1H NMR (800 MHz, CDCl3): δ 7.72 (d, J = 16.0 Hz, 1H),
7.54 (t, J = 1.6 Hz, 1H), 7.43 (d, J = 7.6 Hz, 1H), 7.40−7.38 (m, 1H),
7.35 (t, J = 7.8 Hz, 1H), 6.46 (d, J = 16.0 Hz, 1H).
(E)-3-(4-Fluorophenyl)acrylic acid (25c). White solid (yield 97%).
1H NMR (800 MHz, CD3OD): δ 7.67−7.63 (m, 3H), 7.17−7.12 (m,
2H), 6.43 (d, J = 15.9 Hz, 1H).
(E)-3-(4-Chlorophenyl)acrylic acid (25d). White solid (yield 98%).
1H NMR (500 MHz, DMSO-d6): δ 12.51 (s, 1H), 7.78 (d, J = 8.5 Hz,
2H), 7.64 (d, J = 16.1 Hz, 1H), 7.53 (d, J = 8.5 Hz, 2H), 6.61 (d, J =
16.0 Hz, 1H).
(E)-3-(4-(Trifluoromethyl)phenyl)acrylic acid (25e). White solid
(yield 97%). 1H NMR (800 MHz, DMSO-d6): δ 12.61 (s, 1H), 7.92
(d, J = 8.1 Hz, 2H), 7.76 (d, J = 8.1 Hz, 2H), 7.66 (d, J = 16.0 Hz,
1H), 6.68 (d, J = 16.0 Hz, 1H).
(E)-3-(2,3-Dichlorophenyl)acrylic acid (25f). White solid (yield
94%). 1H NMR (800 MHz, DMSO-d6): δ 12.72 (br, 1H), 7.89 (dd, J
= 7.9, 1.4 Hz, 1H), 7.87 (d, J = 15.9 Hz, 1H), 7.70 (dd, J = 8.0, 1.4
Hz, 1H), 7.41 (t, J = 7.9 Hz, 1H), 6.63 (d, J = 15.9 Hz, 1H).
General Method for the Preparation of Acrylamides 26a−f.
To a solution of acrylacids 25a−f in DMF (0.1 mol/L) were added
N,O-dimethylhydroxylamine hydrochloride (1.2 equiv), HATU (1.5
equiv), and NaHCO3 (3.0 equiv), and the mixture was stirred at room
temperature overnight. The mixture was diluted with ethyl acetate
and washed with water and brine. The organic layer was separated,
concentrated, and purified by flash chromatography (0−30% EtOAc
in petroleum ether) to give the acrylamides 26a−f.
(E)-3-(3-Fluorophenyl)-N-methoxy-N-methylacrylamide (26a).
Colorless oil (yield 94%). 1H NMR (800 MHz, CDCl3): δ 7.68 (d,
J = 15.8 Hz, 1H), 7.36−7.31 (m, 2H), 7.28−7.25 (m, 1H), 7.07−7.04
(m, 1H), 7.02 (d, J = 15.8 Hz, 1H), 3.77 (s, 3H), 3.31 (s, 3H). HRMS
(ESI): m/z calcd for C11H13FNO2
+ [M + H]+, 210.0925; found,
210.0921.
(E)-3-(3-Chlorophenyl)-N-methoxy-N-methylacrylamide (26b).
Colorless oil (yield 97%). 1H NMR (800 MHz, CDCl3): δ 7.66 (d,
J = 15.8 Hz, 1H), 7.55 (t, J = 1.8 Hz, 1H), 7.42 (dt, J = 7.1, 1.7 Hz,
1H), 7.35−7.30 (m, 2H), 7.02 (d, J = 15.8 Hz, 1H), 3.77 (s, 3H),
3.31 (s, 3H). HRMS (ESI): m/z calcd for C11H13ClNO2
+ [M + H]+,
226.0629; found, 226.0623.
(E)-3-(4-Fluorophenyl)-N-methoxy-N-methylacrylamide (26c).
Colorless oil (yield 92%). 1H NMR (800 MHz, CDCl3): δ 7.69 (d,
J = 15.8 Hz, 1H), 7.57−7.53 (m, 2H), 7.09−7.05 (m, 2H), 6.96 (d, J
= 15.8 Hz, 1H), 3.76 (s, 3H), 3.31 (s, 3H). HRMS (ESI): m/z calcd
for C11H13FNO2
+ [M + H]+, 210.0925; found, 210.0918.
(E)-3-(4-Chlorophenyl)-N-methoxy-N-methylacrylamide (26d).
Colorless oil (yield 96%). 1H NMR (500 MHz, CDCl3): δ 7.68 (d,
J = 15.8 Hz, 1H), 7.50 (d, J = 8.5 Hz, 2H), 7.35 (d, J = 8.5 Hz, 2H),
7.01 (d, J = 15.8 Hz, 1H), 3.77 (s, 3H), 3.31 (s, 3H). HRMS (ESI):
m/z calcd for C11H13ClNO2
+ [M + H]+, 226.0629; found, 226.0625.
(E)-N-Methoxy-N-methyl-3-(4-(trifluoromethyl)phenyl)-
acrylamide (26e). Colorless oil (yield 81%). 1H NMR (800 MHz,
CDCl3): δ 7.74 (d, J = 15.8 Hz, 1H), 7.66 (d, J = 8.2 Hz, 2H), 7.64
(d, J = 8.2 Hz, 2H), 7.10 (d, J = 15.8 Hz, 1H), 3.78 (s, 3H), 3.32 (s,
3H). HRMS (ESI): m/z calcd for C12H13F3NO2
+ [M + H]+,
260.0893; found, 260.0889.
(E)-3-(2,3-Dichlorophenyl)-N-methoxy-N-methylacrylamide
(26f). Colorless oil (yield 90%). 1H NMR (800 MHz, CDCl3): δ 8.11
(d, J = 15.7 Hz, 1H), 7.55 (dd, J = 7.8, 1.5 Hz, 1H), 7.47 (dd, J = 8.0,
1.5 Hz, 1H), 7.22 (t, J = 7.9 Hz, 1H), 7.00 (d, J = 15.8 Hz, 1H), 3.76
(s, 3H), 3.32 (s, 3H). HRMS (ESI): m/z calcd for C11H12Cl2NO2
+
[M + H]+, 260.0240; found, 260.0237.
General Method for the Preparation of 27a−f. Trimethylsul-
foxonium iodide (1.5−2.0 equiv) was suspended in anhydrous DMSO
(∼2 mol/L), and sodium hydride (1.5−2.0 equiv) was added in small
portions. The mixture was stirred at room temperature from 0.5 to 1 h
to afford a clear solution. A solution of acrylamides 26a−f (1.0 equiv)
in anhydrous DMSO (2 mol/L) was then slowly added, and the
solution was stirred at room temperature overnight. The mixture was
diluted with ethyl acetate and washed with water and brine. The
organic layer was separated, concentrated, and purified by flash
chromatography (0−30% ethyl acetate in petroleum ether) to give
27a−f.
2-(3-Fluorophenyl)-N-methoxy-N-methylcyclopropane-1-car-
boxamide (27a). Colorless oil (yield 71%). 1H NMR (800 MHz,
CDCl3): δ 7.26−7.22 (m, 1H), 6.94 (d, J = 7.7 Hz, 1H), 6.89 (td, J =
8.4, 2.5 Hz, 1H), 6.82−6.79 (m, 1H), 3.71 (s, 3H), 3.25 (s, 3H),
2.52−2.47 (m, 1H), 2.42 (s, 1H), 1.67−1.62 (m, 1H), 1.32−1.28 (m,
1H). HRMS (ESI): m/z calcd for C12H15FNO2
+ [M + H]+, 224.1081;
found, 224.1076.
2-(3-Chlorophenyl)-N-methoxy-N-methylcyclopropane-1-car-
boxamide (27b). Colorless oil (yield 77%). 1H NMR (800 MHz,
CDCl3): δ 7.22−7.18 (m, 1H), 7.18−7.15 (m, 1H), 7.08 (t, J = 1.8
Hz, 1H), 7.03−7.01 (m, 1H), 3.70 (s, 3H), 3.23 (s, 3H), 2.48−2.45
(m, 1H), 2.41 (s, 1H), 1.65−1.60 (m, 1H), 1.31−1.26 (m, 1H).
HRMS (ESI): m/z calcd for C12H15ClNO2
+ [M + H]+, 240.0786;
found, 240.0786.
2-(4-Fluorophenyl)-N-methoxy-N-methylcyclopropane-1-car-
boxamide (27c). Colorless oil (yield 73%). 1H NMR (800 MHz,
CDCl3): δ 7.10−7.07 (m, 2H), 6.99−6.94 (m, 2H), 3.69 (s, 3H), 3.23
(s, 3H), 2.52−2.45 (m, 1H), 2.35 (s, 1H), 1.62−1.58 (m, 1H), 1.28−
1.21 (m, 1H). HRMS (ESI): m/z calcd for C12H15FNO2
+ [M + H]+,
224.1081; found, 224.1076.
2-(4-Chlorophenyl)-N-methoxy-N-methylcyclopropane-1-car-
boxamide (27d). Colorless oil (yield 82%). 1H NMR (800 MHz,
CDCl3): δ 7.24 (d, J = 8.5 Hz, 2H), 7.05 (d, J = 8.4 Hz, 2H), 3.69 (s,
3H), 3.23 (s, 3H), 2.48−2.45 (m, 1H), 2.40−2.34 (m, 1H), 1.65−
1.61 (m, 1H), 1.29−1.25 (m, 1H). HRMS (ESI): m/z calcd for
C12H15ClNO2
+ [M + H]+, 240.0786; found, 240.0780.
N-Methoxy-N-methy l -2 - (4 - ( t r ifluoromethy l )pheny l ) -
cyclopropane-1-carboxamide (27e). White solid (yield 76%). 1H
NMR (800 MHz, CDCl3): δ 7.53 (d, J = 8.1 Hz, 2H), 7.23 (d, J = 8.1
Hz, 2H), 3.70 (s, 3H), 3.24 (s, 3H), 2.57−2.53 (m, 1H), 2.46 (s, 1H),
1.71−1.67 (m, 1H), 1.36−1.32 (m, 1H). HRMS (ESI): m/z calcd for
C13H15F3NO2
+ [M + H]+, 274.1049; found, 274.1045.
2-(2,3-Dichlorophenyl)-N-methoxy-N-methylcyclopropane-1-
carboxamide (27f). Colorless oil (yield 77%). 1H NMR (800 MHz,
CDCl3): δ 7.34 (dd, J = 8.0, 1.5 Hz, 1H), 7.14 (t, J = 7.9 Hz, 1H),
7.00 (d, J = 7.5 Hz, 1H), 3.73 (s, 3H), 3.26 (s, 3H), 2.78−2.73 (m,
1H), 2.32 (s, 1H), 1.66−1.63 (m, 1H), 1.35−1.31 (m, 1H). HRMS
(ESI): m/z calcd for C12H14Cl2NO2
+ [M + H]+, 274.0396; found,
274.0389.
General Method for the Preparation of Aldehydes 28a−f. A
solution of 27a−f (1.0 equiv) in anhydrous THF (0.1−0.2 mmol/
mL) was cooled to −78 °C under argon. To this solution was added
slowly DIBAL-H (1.0 M solution in THF, 2.0 equiv), and the solution
was stirred at −78 °C for 2−3 h. A saturated aqueous solution of
Rochelle’s salt was added to quench the reaction, and the mixture was
warmed to room temperature, stirred for 1 h, and filtered. The solid
was washed with ethyl acetate, and the filtrate was extracted with the
same solvent. The combined organic phases were washed with brine,
dried, and concentrated to give the aldehydes 28a−f as a colorless oil,
which were used in the next step without further purification.
General Method for the Preparation of Amines 29a−c. To a
solution of crude aldehydes 20a−c (1.0 equiv) in THF (0.25 mol/L)
was added propylamine (5.0 equiv), NaHB(AcO)3 (2.0−2.5 equiv),
and AcOH (1.0 equiv) successively. The mixture was stirred at room
temperature overnight. Methanol was added to quench the reaction,
and the mixture was stirred at room temperature for 15 min. The
solvent was evaporated under a vacuum, and the residue formed was
purified by flash chromatography (0−10% methanol in dichloro-
methane) to give propyl amines 29a−c.
N-(4-(Propylamino)butyl)-2-naphthamide (29a). White solid
(yield 44%). 1H NMR (600 MHz, DMSO-d6): δ 8.83−8.74 (m,
2H), 8.49 (s, 1H), 8.04−7.94 (m, 4H), 7.65−7.57 (m, 2H), 3.36−
3.33 (m, 2H), 2.94−2.89 (m, 2H), 2.84−2.79 (m, 2H), 1.74−1.68
(m, 2H), 1.66−1.59 (m, 4H), 0.91 (t, J = 7.4 Hz, 3H). HRMS (ESI):
m/z calcd for C18H25N2O
+ [M + H]+, 285.1961; found, 285.1958.
N-(4-(Propylamino)butyl)-1H-indole-2-carboxamide (29b).
White solid (yield 64%). 1H NMR (800 MHz, CD3OD): δ 7.59 (d,
J = 8.0 Hz, 1H), 7.44 (d, J = 8.2 Hz, 1H), 7.21 (t, J = 7.6 Hz, 1H),
7.08−7.05 (m, 2H), 3.45 (t, J = 6.6 Hz, 2H), 3.05−3.01 (m, 2H),
2.94−2.91 (m, 2H), 1.79−1.74 (m, 2H), 1.74−1.65 (m, 4H), 1.00 (t,
J = 7.3 Hz, 3H). HRMS (ESI): m/z calcd for C16H24N3O
+ [M + H]+,
274.1914; found, 274.1910.
N-(4-(Propylamino)butyl)-4-(pyridin-2-yl)benzamide (29c). Yel-
low oil (yield 46%). 1H NMR (600 MHz, CD3OD): δ 8.65 (dt, J =
4.9, 1.3 Hz, 1H), 8.08−8.05 (m, 2H), 7.97−7.92 (m, 4H), 7.43−7.39
(m, 1H), 3.46 (t, J = 6.5 Hz, 2H), 3.05−2.99 (m, 2H), 2.94−2.90 (m,
2H), 1.78−1.66 (m, 6H), 1.01 (t, J = 7.5 Hz, 3H). HRMS (ESI): m/z
calcd for C19H26N3O
+ [M + H]+, 312.2070; found, 312.2067.
General Method for the Preparation of 30a−r. To a solution
of crude aldehydes 28a−f (1.0 equiv) in CH3CN (0.03−0.05 mol/L)
were added amine 29a−c (1.0 equiv), NaHB(AcO)3 (2.0 equiv), and
AcOH (1.0 equiv), and the reaction mixture was stirred at room
temperature overnight. Methanol was added to afford a clear solution,
which was stirred at room temperature for 15−30 min. The solution
was concentrated and purified by flash chromatography (0−6%
methanol in dichloromethane) to give title products as a colorless oil.
The free amines 30a−r were converted to corresponding HCl salts
using a similar method as depicted for 17a.
N-(4-(((2-(3-Fluorophenyl)cyclopropyl)methyl)(propyl)amino)-
butyl)-2-naphthamide Hydrochloride (30a). White solid (yield
68%). HPLC: 98.1% (λ = 254 nm, tR = 20.2 min).
1H NMR (800
MHz, CD3OD): δ 8.39 (s, 1H), 7.99−7.92 (m, 3H), 7.91−7.87 (m,
1H), 7.62−7.56 (m, 2H), 7.27−7.23 (m, 1H), 6.96 (t, J = 7.7 Hz,
1H), 6.91−6.85 (m, 2H), 3.52−3.49 (m, 2H), 3.34−3.25 (m, 4H),
3.24−3.14 (m, 2H), 2.10−2.06 (m, 1H), 1.89−1.82 (m, 2H), 1.81−
1.72 (m, 4H), 1.51−1.45 (m, 1H), 1.25−1.21 (m, 1H), 1.17−1.14
(m, 1H), 1.00 (t, J = 7.4 Hz, 3H). 13C NMR (201 MHz, CD3OD): δ
170.37, 164.52 (d, JCF = 244.0 Hz), 145.68 (d, JCF = 7.0 Hz), 136.29,
134.06, 132.79, 131.19 (d, JCF = 8.5 Hz), 129.99, 129.38, 128.89,
128.79, 128.77, 127.91, 124.82, 122.80, 113.73 (d, JCF = 21.8 Hz),
113.37 (d, JCF = 22.1 Hz), 58.22, 55.93, 53.96, 40.07, 28.00, 23.61,
22.80, 19.42, 18.75, 15.60, 11.44. HRMS (ESI): m/z calcd for
C28H34FN2O
+ [M + H]+, 433.2650; found, 433.2645.
N-(4-(((2-(3-Fluorophenyl)cyclopropyl)methyl)(propyl)amino)-
butyl)-1H-indole-2-carboxamide Hydrochloride (30b). White solid
(yield 36%). HPLC: 98.8% (λ = 280 nm, tR = 16.3 min).
1H NMR
(800 MHz, CD3OD): δ 7.60 (dd, J = 8.0, 2.5 Hz, 1H), 7.45 (d, J = 8.3
Hz, 1H), 7.25−7.20 (m, 2H), 7.11 (d, J = 3.3 Hz, 1H), 7.06 (t, J = 7.5
Hz, 1H), 6.93 (t, J = 8.7 Hz, 1H), 6.89−6.85 (m, 2H), 3.47−3.43 (m,
2H), 3.29−3.21 (m, 4H), 3.20−3.09 (m, 2H), 2.09−2.03 (m, 1H),
1.87−1.79 (m, 2H), 1.78−1.65 (m, 4H), 1.47−1.42 (m, 1H), 1.22−
1.19 (m, 1H), 1.16−1.11 (m, 1H), 0.97 (t, J = 7.3 Hz, 3H). 13C NMR
(201 MHz, CD3OD): δ 164.35, 164.50 (d, JCF = 243.8 Hz), 145.19
(d, JCF = 7.7 Hz), 138.31, 132.09, 131.26 (d, JCF = 8.6 Hz), 128.97,
125.13, 122.87, and 122.83 (d, JCF = 2.7 Hz), 122.76, 121.24, 113.88
(d, JCF = 21.4 Hz), 113.45 (d, JCF = 22.2 Hz), 113.08, 104.51 and
104.50, 58.05 and 58.01, 55.69 and 55.60, 53.87 and 53.72, 39.33,
27.86 and 27.84, 23.55 and 23.51, 22.27 and 22.21, 18.67 and 18.62,
18.32 and 18.27, 15.62 and 15.60, 11.21, and 11.19. HRMS (ESI): m/
z calcd for C26H33FN3O
+ [M + H]+, 422.2602; found, 422.2609.
N-(4-(((2-(3-Fluorophenyl)cyclopropyl)methyl)(propyl)amino)-
butyl)-4-(pyridin-2-yl)benzamide Hydrochloride (30c). White solid
(yield 55%). HPLC: 99.4% (λ = 254 nm, tR = 12.7 min).
1H NMR
(800 MHz, CD3OD): δ 8.90 (d, J = 5.3 Hz, 1H), 8.72 (t, J = 7.9 Hz,
1H), 8.45 (d, J = 8.2 Hz, 1H), 8.15 (d, J = 8.1 Hz, 2H), 8.12−8.05
(m, 3H), 7.30−7.23 (m, 1H), 7.02−6.96 (m, 1H), 6.92−6.86 (m,
2H), 3.52−3.46 (m, 2H), 3.36−3.28 (m, 4H), 3.25−3.17 (m, 2H),
2.14−2.11 (m, 1H), 1.90−1.84 (m, 2H), 1.83−1.78 (m, 2H), 1.77−
1.69 (m, 2H), 1.53−1.48 (m, 1H), 1.26−1.22 (m, 1H), 1.21−1.16
(m, 1H), 1.01 (t, J = 7.4 Hz, 3H). 13C NMR (201 MHz, CD3OD): δ
168.76, 164.52 (d, JCF = 244.1 Hz), 153.15, 148.32, 145.30, 143.54,
138.92, 135.10, 131.29 and 131.25, 129.75 (2C), 129.61 (2C),
127.60, 127.21, 122.92, 113.88 (d, JCF = 21.4 Hz), 113.48 (d, JCF =
22.2 Hz), 58.02, 55.72 and 55.61, 53.85and 53.71, 40.06 and 40.04,
27.68 and 27.65, 23.56, 22.39 and 22.29, 18.69, 18.33 and 18.30,
15.66 and 15.65, 11.26, and 11.24. HRMS (ESI): m/z calcd for
C29H35FN3O
+ [M + H]+, 460.2759; found, 460.2769.
N-(4-(((2-(3-Chlorophenyl)cyclopropyl)methyl)(propyl)amino)-
butyl)-2-naphthamide Hydrochloride (30d). White solid (yield
46%). HPLC: 99.8% (λ = 254 nm, tR = 25.3 min).
1H NMR (800
MHz, CD3OD): δ 8.41 (s, 1H), 7.97 (t, J = 7.3 Hz, 1H), 7.95−7.89
(m, 3H), 7.60−7.55 (m, 2H), 7.23−7.20 (m, 1H), 7.17−7.14 (m,
2H), 7.06−7.04 (m, 1H), 3.52−3.49 (m, 2H), 3.34−3.12 (m, 6H),
2.09−2.05 (m, 1H), 1.89−1.82 (m, 2H), 1.81−1.72 (m, 4H), 1.51−
1.45 (m, 1H), 1.24−1.19 (m, 1H), 1.17−1.13 (m, 1H), 0.99 (t, J =
7.3 Hz, 3H). 13C NMR (201 MHz, CD3OD): δ 170.34, 144.67,
136.28, 135.46, 134.04, 132.70, 131.05, 130.01, 129.39, 128.90,
128.81, 128.78, 127.91, 127.31, 126.96, 125.35 and 125.30, 124.83,
58.03, 55.72 and 55.60, 53.88 and 53.74, 39.87 and 39.85, 27.82 and
27.79, 23.43, 22.31 and 22.21, 18.62 and 18.60, 18.33 and 18.29,
15.54, 11.24, and 11.22. HRMS (ESI): m/z calcd for C28H34ClN2O
+
[M + H]+, 449.2354; found, 449.2361.
N-(4-(((2-(3-Chlorophenyl)cyclopropyl)methyl)(propyl)amino)-
butyl)-1H-indole-2-carboxamide Hydrochloride (30e). White solid
(yield 8%). HPLC: 97.2% (λ = 280 nm, tR = 20.5 min).
1H NMR
(800 MHz, CD3OD): δ 7.60 (dd, J = 8.0, 2.8 Hz, 1H), 7.47−7.44 (m,
1H), 7.23−7.19 (m, 2H), 7.16−7.13 (m, 2H), 7.12−7.11 (m, 1H),
7.06 (t, J = 7.5 Hz, 1H), 7.05−7.01 (m, 1H), 3.47−3.43 (m, 2H),
3.30−3.19 (m, 4H), 3.19−3.09 (m, 2H), 2.07−2.01 (m, 1H), 1.87−
1.79 (m, 2H), 1.78−1.68 (m, 4H), 1.48−1.42 (m, 1H), 1.23−1.18
(m, 1H), 1.15−1.10 (m, 1H), 0.99−0.95 (m, 3H). 13C NMR (201
MHz, CD3OD): δ 164.34, 144.65, 138.31, 135.45, 132.09, 131.06,
128.97, 127.30, 126.95, 125.33 and 125.27, 125.13, 122.77 and
122.76, 121.24, 113.09, 104.55, 58.06 and 58.02, 55.69 and 55.62,
53.87 and 53.73, 39.33, 27.86 and 27.83, 23.43 and 23.41, 22.27 and
22.22, 18.64 and 18.59, 18.32 and 18.28, 15.53, 11.22, and 11.21.
HRMS (ESI): m/z calcd for C26H33ClN3O
+ [M + H]+, 438.2307;
found, 438.2317.
N-(4-(((2-(3-Chlorophenyl)cyclopropyl)methyl)(propyl)amino)-
butyl)-4-(pyridin-2-yl)benzamide Hydrochloride (30f). White solid
(yield 46%). HPLC: 99.9% (λ = 254 nm, tR = 14.2 min).
1H NMR
(800 MHz, CD3OD): δ 8.91 (d, J = 5.7 Hz, 1H), 8.75−8.71 (m, 1H),
8.46 (d, J = 8.1 Hz, 1H), 8.16 (d, J = 8.1 Hz, 2H), 8.12−8.07 (m,
3H), 7.26−7.23 (m, 1H), 7.19−7.16 (m, 2H), 7.11−7.08 (m, 1H),
3.51−3.47 (m, 2H), 3.36−3.27 (m, 4H), 3.25−3.16 (m, 2H), 2.13−
2.09 (m, 1H), 1.91−1.84 (m, 2H), 1.84−1.78 (m, 2H), 1.77−1.72
(m, 2H), 1.54−1.49 (m, 1H), 1.26−1.22 (m, 1H), 1.20−1.16 (m,
1H), 1.01 (t, J = 7.3 Hz, 3H). 13C NMR (201 MHz, CD3OD): δ
168.72, 153.08, 148.42, 144.76, 143.46, 138.94, 135.45, 134.99,
131.08, 129.77 (2C), 129.62 (2C), 127.65, 127.30, 127.24, 126.98,
125.39 and 125.36, 58.02, 55.72 and 55.61, 53.83 and 53.71, 40.06
and 40.04, 27.67 and 27.65, 23.45, 22.38 and 22.29, 18.67 and 18.66,
18.33 and 18.30, 15.58, 11.27, and 11.25. HRMS (ESI): m/z calcd for
C29H35ClN3O
+ [M + H]+, 476.2463; found, 476.2468.
N-(4-(((2-(4-Fluorophenyl)cyclopropyl)methyl)(propyl)amino)-
butyl)-2-naphthamide Hydrochloride (30g). White solid (yield
38%). HPLC: 99.5% (λ = 254 nm, tR = 20.6 min).
1H NMR (800
MHz, CD3OD): δ 8.40 (s, 1H), 7.97 (t, J = 7.3 Hz, 1H), 7.95−7.89
(m, 3H), 7.61−7.55 (m, 2H), 7.15−7.11 (m, 2H), 6.99−6.95 (m,
2H), 3.53−3.48 (m, 2H), 3.33−3.24 (m, 4H), 3.23−3.14 (m, 2H),
2.08−2.04 (m, 1H), 1.90−1.82 (m, 2H), 1.81−1.72 (m, 4H), 1.44−
1.38 (m, 1H), 1.18−1.15 (m, 1H), 1.13−1.09 (m, 1H), 0.99 (t, J =
7.3 Hz, 3H). 13C NMR (201 MHz, CD3OD): δ 170.35, 162.88 (d, JCF
= 243.0 Hz), 137.95 and 137.93, 136.29, 134.05, 132.70, 130.00,
129.40, 128.92, 128.80 (d, JCF = 2.7 Hz), 128.62, 128.61 (d, JCF = 7.9
Hz), 128.58, 127.92, 124.82, 116.16 (d, JCF = 21.6 Hz, 2C), 58.15,
55.74 and 55.61, 53.89 and 53.71, 39.87 and 39.85, 27.82 and 27.80,
23.12 and 23.10, 22.33 and 22.20, 18.35 and 18.29, 18.22 and 18.20,
15.21 and 15.19, 11.24, and 11.22. HRMS (ESI): m/z calcd for
C28H34FN2O
+ [M + H]+, 433.2650; found, 433.2645.
N-(4-(((2-(4-Fluorophenyl)cyclopropyl)methyl)(propyl)amino)-
butyl)-1H-indole-2-carboxamide Hydrochloride (30h). White solid
(yield 16%). HPLC: 98.0% (λ = 280 nm, tR = 16.9 min).
1H NMR
(800 MHz, CD3OD): δ 7.60 (dd, J = 8.0, 2.5 Hz, 1H), 7.47−7.44 (m,
1H), 7.23−7.20 (m, 1H), 7.14−7.05 (m, 4H), 6.97−6.92 (m, 2H),
3.47−3.43 (m, 2H), 3.28−3.21 (m, 4H), 3.18−3.11 (m, 2H), 2.05−
1.99 (m, 1H), 1.86−1.80 (m, 2H), 1.77−1.67 (m, 4H), 1.40−1.35
(m, 1H), 1.16−1.12 (m, 1H), 1.10−1.06 (m, 1H), 1.00−0.93 (m,
3H). 13C NMR (201 MHz, CD3OD): δ 164.32, 162.86 (d, JCF =
242.5 Hz), 138.31, 137.92 (d, JCF = 2.8 Hz), 132.11 and 132.09,
128.97, 128.59, and 128.57 (d, JCF = 7.9 Hz, 2C), 125.14, 122.78 and
122.76, 121.25, 116.15 (d, JCF = 21.7 Hz, 2C), 113.09, 104.55 and
104.51, 58.17 and 58.14, 55.72 and 55.64, 53.86 and 53.68, 39.34,
27.84 and 27.83, 23.11 and 23.08, 22.30 and 22.20, 18.33 and 18.28,
18.22 and 18.21, 15.23 and 15.21, 11.22, and 11.21. HRMS (ESI): m/
z calcd for C26H33FN3O
+ [M + H]+, 422.2602; found, 422.2611.
N-(4-(((2-(4-Fluorophenyl)cyclopropyl)methyl)(propyl)amino)-
butyl)-4-(pyridin-2-yl)benzamide Hydrochloride (30i). White solid
(yield 36%). HPLC: 96.2% (λ = 254 nm, tR = 12.5 min).
1H NMR
(800 MHz, CD3OD): δ 8.90−8.86 (m, 1H), 8.67−8.62 (m, 1H),
8.42−8.38 (m, 1H), 8.14−8.11 (m, 2H), 8.08−8.06 (m, 2H), 8.05−
8.01 (m, 1H), 7.18−7.14 (m, 2H), 7.02−6.98 (m, 2H), 3.50−3.47
(m, 2H), 3.33−3.26 (m, 4H), 3.24−3.16 (m, 2H), 2.11−2.06 (m,
1H), 1.89−1.82 (m, 2H), 1.81−1.71 (m, 4H), 1.46−1.41 (m, 1H),
1.21−1.18 (m, 1H), 1.15−1.11 (m, 1H), 1.02 (t, J = 7.4 Hz, 3H). 13C
NMR (201 MHz, CD3OD): δ 168.76, 162.85 (d, JCF = 242.4 Hz),
153.23, 148.03, 143.75, 138.80, 138.03, 135.31, 129.72 (2C), 129.56
(2C), 128.65 (d, JCF = 7.6 Hz, 2C), 127.44, 127.13, 116.15 (d, JCF =
21.6 Hz, 2C), 58.14 and 58.13, 55.70 and 55.60, 53.82 and 53.67,
40.07 and 40.05, 27.66 and 27.64 23.13 and 23.11, 22.40 and 22.27,
18.34 and 18.29, 18.27 and 18.25, 15.26 and 15.24, 11.28, and 11.27.
HRMS (ESI): m/z calcd for C29H35FN3O
+ [M + H]+, 460.2759;
found, 460.2754.
N-(4-(((2-(4-Chlorophenyl)cyclopropyl)methyl)(propyl)amino)-
butyl)-2-naphthamide Hydrochloride (30j). White solid (yield
46%). HPLC: 98.9% (λ = 254 nm, tR = 25.4 min).
1H NMR (800
MHz, CD3OD): δ 8.40 (d, J = 4.1 Hz, 1H), 7.97 (t, J = 7.7 Hz, 1H),
7.95−7.88 (m, 3H), 7.60−7.55 (m, 2H), 7.24−7.21 (m, 2H), 7.11−
7.08 (m, 2H), 3.53−3.47 (m, 2H), 3.34−3.24 (m, 4H), 3.22−3.12
(m, 2H), 2.08−2.03 (m, 1H), 1.89−1.82 (m, 2H), 1.81−1.72 (m,
4H), 1.47−1.42 (m, 1H), 1.20−1.16 (m, 1H), 1.15−1.11 (m, 1H),
0.99 (t, J = 7.4 Hz, 3H). 13C NMR (201 MHz, CD3OD): δ 170.36,
140.97, 136.29, 134.05, 132.89, 132.70, 130.01, 129.58, and 129.57
(2C), 129.40, 128.92, 128.80, and 128.79 (2C), 128.48 and 128.46
(2C), 127.92, 124.82, 58.08, 55.76 and 55.65, 53.88 and 53.71, 39.86
and 39.84, 27.82 and 27.79, 23.25 and 23.21, 22.32 and 22.17, 18.49
and 18.45, 18.34 and 18.29, 15.47 and 15.43, 11.24, and 11.22. HRMS
(ESI): m/z calcd for C28H34ClN2O
+ [M + H]+, 449.2354; found,
449.2356.
N-(4-(((2-(4-Chlorophenyl)cyclopropyl)methyl)(propyl)amino)-
butyl)-1H-indole-2-carboxamide Hydrochloride (30k). White solid
(yield 36%). HPLC: 97.1% (λ = 280 nm, tR = 20.7 min).
1H NMR
(800 MHz, CD3OD): δ 7.60 (dd, J = 8.1, 2.8 Hz, 1H), 7.45 (d, J = 8.2
Hz, 1H), 7.23−7.20 (m, 3H), 7.11−7.09 (m, 1H), 7.09−7.05 (m,
3H), 3.48−3.43 (m, 2H), 3.30−3.21 (m, 4H), 3.19−3.10 (m, 2H),
2.05−2.00 (m, 1H), 1.87−1.79 (m, 2H), 1.79−1.68 (m, 4H), 1.44−
1.38 (m, 1H), 1.19−1.15 (m, 1H), 1.13−1.09 (m, 1H), 0.98 (t, J =
7.4 Hz, 3H). 13C NMR (201 MHz, CD3OD): δ 164.36, 140.94,
138.32, 132.88, 132.08, 129.58, and 129.56 (2C), 128.98, 128.45, and
128.43 (2C), 125.14, 122.77, 121.25, 113.09, 104.49, 58.10 and 58.07,
55.76 and 55.69, 53.88 and 53.70, 39.31 and 39.29, 27.86 and 27.84,
23.25 and 23.20, 22.29 and 22.18, 18.47, 18.34 and 18.29, 15.46 and
15.41, 11.21, and 11.20. HRMS (ESI): m/z calcd for C26H33ClN3O
+
[M + H]+, 438.2307; found, 423.2307.
N-(4-(((2-(4-Chlorophenyl)cyclopropyl)methyl)(propyl)amino)-
butyl)-4-(pyridin-2-yl)benzamide Hydrochloride (30l). White solid
(yield 47%). HPLC: 99.5% (λ = 254 nm, tR = 14.0 min).
1H NMR
(800 MHz, CD3OD): δ 8.91 (d, J = 5.5 Hz, 1H), 8.72 (t, J = 7.9 Hz,
1H), 8.46 (d, J = 8.1 Hz, 1H), 8.16−8.14 (m, 2H), 8.12−8.06 (m,
3H), 7.26−7.23 (m, 2H), 7.16−7.12 (m, 2H), 3.52−3.45 (m, 2H),
3.35−3.27 (m, 4H), 3.24−3.15 (m, 2H), 2.12−2.07 (m, 1H), 1.90−
1.84 (m, 2H), 1.82−1.77 (m, 2H), 1.76−1.72 (m, 2H), 1.50−1.45
(m, 1H), 1.23−1.19 (m, 1H), 1.18−1.14 (m, 1H), 1.01 (t, J = 7.4 Hz,
3H). 13C NMR (201 MHz, CD3OD): δ 168.74, 153.10, 148.39,
143.48, 141.07, 138.94, 135.02, 132.85, 129.76 (2C), 129.62 (2C),
129.57 (2C), 128.53 and 128.52 (2C), 127.64, 127.24, 58.07 and
58.04, 55.76 and 55.65, 53.83 and 53.67, 40.0 and, 40.04, 27.67 and
27.65, 23.27 and 23.22, 22.40 and 22.25, 18.56 and 18.48, 18.35 and
18.31, 15.50 and 15.46, 11.27, and 11.25. HRMS (ESI): m/z calcd for
C29H35ClN3O
+ [M + H]+, 476.2463; found, 476.2473.
N-(4-(Propyl((2-(4-(trifluoromethyl)phenyl)cyclopropyl)methyl)-
amino)butyl)-2-naphthamide Hydrochloride (30m). White solid
(yield 44%). HPLC: 98.0% (λ = 254 nm, tR = 25.1 min).
1H NMR
(800 MHz, CD3OD): δ 8.42 (d, J = 3.3 Hz, 1H), 7.99 (t, J = 7.9 Hz,
1H), 7.97−7.90 (m, 3H), 7.62−7.56 (m, 2H), 7.54 (d, J = 7.9 Hz,
2H), 7.33−7.29 (m, 2H), 3.56−3.49 (m, 2H), 3.37−3.27 (m, 4H),
3.24−3.15 (m, 2H), 2.19−2.14 (m, 1H), 1.90−1.84 (m, 2H), 1.82−
1.74 (m, 4H), 1.59−1.53 (m, 1H), 1.31−1.28 (m, 1H), 1.25−1.19
(m, 1H), 1.01 (t, J = 7.3 Hz, 3H). 13C NMR (201 MHz, CD3OD): δ
170.27, 147.01, 136.24, 134.02, 132.69, 130.00, 129.37, 129.22,
128.89, 128.82, 128.77, 127.89, 127.42 (2C), 126.35 (q, JCF = 3.3 Hz,
2C), 125.75 (q, JCF = 270.7 Hz), 124.85, 57.92, 55.69 and 55.62,
53.85 and 53.72, 39.88 and 39.86, 27.77 and 27.74, 23.59 and 23.56,
22.30 and 22.17, 19.01 and 18.99, 18.30 and 18.27, 16.04, 11.25, and
11.23. HRMS (ESI): m/z calcd for C29H34F3N2O
+ [M + H]+,
483.2618; found, 483.2617.
N-(4-(Propyl((2-(4-(trifluoromethyl)phenyl)cyclopropyl)methyl)-
amino)butyl)-1H-indole-2-carboxamide Hydrochloride (30n). Yel-
low oil (yield 11%). HPLC: 99.0% (λ = 280 nm, tR = 16.5 min).
1H
NMR (800 MHz, CD3OD): δ 7.60 (dd, J = 8.0, 3.1 Hz, 1H), 7.53−
7.50 (m, 2H), 7.45 (dd, J = 8.2, 3.3 Hz, 1H), 7.28−7.25 (m, 2H),
7.23−7.21 (m, 1H), 7.10 (s, 1H), 7.08−7.05 (m, 1H), 3.48−3.44 (m,
2H), 3.30−3.22 (m, 4H), 3.20−3.11 (m, 2H), 2.16−2.11 (m, 1H),
1.88−1.80 (m, 2H), 1.79−1.68 (m, 4H), 1.55−1.49 (m, 1H), 1.28−
1.24 (m, 1H), 1.21−1.17 (m, 1H), 0.98 (t, J = 7.3 Hz, 3H). 13C NMR
(201 MHz, CD3OD): δ 164.36, 146.97, 138.32, 132.07, 129.35 (q, JCF
= 32.8 Hz), 128.97, 127.39 (2C), 126.38 (2C), 125.76 (q, JCF = 270.9
Hz), 125.15, 122.76, 121.25, 113.09, 104.52, 58.00 and 57.95, 55.77
and 55.73, 53.90 and 53.74, 39.31 and 39.30, 27.84 and 27.82, 23.60
and 23.56, 22.28 and 22.18, 19.00 and 18.98, 18.33 and 18.29, 16.03
and 16.00, 11.21, and 11.19. HRMS (ESI): m/z calcd for
C27H33F3N3O
+ [M + H]+, 472.2570; found, 472.2572.
N-(4-(Propyl((2-(4-(trifluoromethyl)phenyl)cyclopropyl)methyl)-
amino)butyl)-4-(pyridin-2-yl)benzamide Hydrochloride (30o).
White solid (yield 43%). HPLC: 97.0% (λ = 254 nm, tR = 15.7
min). 1H NMR (800 MHz, CD3OD): δ 8.91 (d, J = 5.8 Hz, 1H), 8.74
(t, J = 7.9 Hz, 1H), 8.51−8.42 (m, 1H), 8.17−8.15 (m, 2H), 8.14−
8.11 (m, 1H), 8.10−8.07 (m, 2H), 7.56 (d, J = 7.8 Hz, 2H), 7.35 (dd,
J = 8.1, 3.6 Hz, 2H), 3.51−3.46 (m, 2H), 3.37−3.32 (m, 3H), 3.30−
3.16 (m, 3H), 2.23−2.17 (m, 1H), 1.92−1.85 (m, 2H), 1.83−1.79
(m, 2H), 1.78−1.70 (m, 2H), 1.63−1.57 (m, 1H), 1.34−1.28 (m,
1H), 1.27−1.22 (m, 1H), 1.01 (t, J = 7.3 Hz, 3H). 13C NMR (201
MHz, CD3OD): δ 168.72, 153.17, 147.95, 147.14, 143.77, 138.73,
135.29, 129.71 (2C), 129.54 (2C), 129.20 (q, JCF = 32.3 Hz), 127.47
(2C), 127.36, 127.10, 126.34 (q, JCF = 3.8 Hz, 2C), 125.75 (q, JCF =
270.8 Hz), 57.92, 55.64 and 55.59, 53.78 and 53.67, 40.06, 27.61 and
27.59, 23.59, 22.34 and 22.24, 19.13 and 19.08, 18.30 and 18.29,
16.09, 11.30, and 11.28. HRMS (ESI): m/z calcd for C30H35F3N3O
+
[M + H]+, 510.2727; found, 510.2731.
N-(4-(((2-(2,3-Dichlorophenyl)cyclopropyl)methyl)(propyl)-
amino)butyl)-2-naphthamide Hydrochloride (30p). White solid
(yield 43%). HPLC: 98.0% (λ = 254 nm, tR = 25.9 min).
1H NMR
(800 MHz, CD3OD): δ 8.39 (d, J = 11.4 Hz, 1H), 8.00−7.92 (m,
3H), 7.91−7.87 (m, 1H), 7.63−7.56 (m, 2H), 7.38 (d, J = 8.0 Hz,
1H), 7.22−7.19 (m, 1H), 7.07 (d, J = 7.8 Hz, 1H), 3.62−3.58 (m,
1H), 3.56−3.51 (m, 2H), 3.41−3.34 (m, 2H), 3.28−3.17 (m, 3H),
2.37−2.33 (m, 1H), 1.93−1.84 (m, 2H), 1.83−1.72 (m, 4H), 1.50−
1.45 (m, 1H), 1.31−1.28 (m, 1H), 1.27−1.23 (m, 1H), 1.05−1.01
(m, 3H). 13C NMR (201 MHz, CD3OD): δ 170.34, 141.88, 136.27,
134.18 and 134.16, 134.04 and 134.03, 133.92, 132.67 and 132.65,
130.01, 129.67, 129.39, 128.92, 128.90, 128.81, 128.78, 127.90,
126.60 and 126.56, 124.80, 57.87 and 57.82, 55.88 and 55.61, 53.96
and 53.66, 39.88 and 39.81, 27.77, 22.41 and 22.37, 22.28 and 22.14,
18.44 and 18.30, 17.34 and 17.31, 14.81 and 14.73, 11.23. HRMS
(ESI): m/z calcd for C28H33Cl2N2O




White solid (yield 16%). HPLC: 98.2% (λ = 280 nm, tR = 24.8
min). 1H NMR (800 MHz, CD3OD): δ 7.60 (d, J = 8.0 Hz, 1H), 7.44
(d, J = 8.2 Hz, 1H), 7.38−7.35 (m, 1H), 7.22 (t, J = 7.6 Hz, 1H), 7.17
(td, J = 7.9, 3.6 Hz, 1H), 7.08−7.05 (m, 2H), 7.04−7.01 (m, 1H),
3.60−3.56 (m, 1H), 3.51−3.46 (m, 2H), 3.37−3.32 (m, 2H), 3.26−
3.15 (m, 3H), 2.35−2.31 (m, 1H), 1.89−1.70 (m, 6H), 1.46−1.40
(m, 1H), 1.27−1.24 (m, 1H), 1.23−1.20 (m, 1H), 1.03−0.99 (m,
3H). 13C NMR (201 MHz, CD3OD): δ 164.38, 141.88, 138.32,
134.18, 133.94, 132.06, 129.67, 128.97, 128.93, 126.57 and 126.54,
125.12, 122.76, 121.23, 113.08, 104.49, 57.88, 55.88 and 55.66, 53.97
and 53.68, 39.33 and 39.30, 27.84 and 27.82, 22.40 and 22.34, 22.25
and 22.20, 18.45 and 18.30, 17.35 and 17.32, 14.78 and 14.71, 11.20,
and 11.19. HRMS (ESI): m/z calcd for C26H32Cl2N3O




White solid (yield 43%). HPLC: 97.9% (λ = 254 nm, tR = 16.3
min). 1H NMR (800 MHz, CD3OD): δ 8.90−8.87 (m, 1H), 8.72−
8.67 (m, 1H), 8.45−8.42 (m, 1H), 8.16−8.11 (m, 2H), 8.10−8.05
(m, 3H), 7.40 (d, J = 7.9 Hz, 1H), 7.24 (t, J = 7.9 Hz, 1H), 7.12−7.09
(m, 1H), 3.62−3.57 (m, 1H), 3.52−3.47 (m, 2H), 3.40−3.32 (m,
2H), 3.28−3.18 (m, 3H), 2.39−2.34 (m, 1H), 1.91−1.84 (m, 2H),
1.83−1.73 (m, 4H), 1.51−1.45 (m, 1H), 1.32−1.25 (m, 2H), 1.06−
1.01 (m, 3H). 13C NMR (201 MHz, CD3OD): δ 168.75, 153.10,
148.38, 143.49, 141.98, 138.92, 135.02, 134.18, 133.93, 129.75, and
129.74 (2C), 129.68, 129.61 (2C), 128.98, 127.63, 127.23, 126.66
and 126.61, 57.83 and 57.80, 55.87 and 55.58, 53.92 and 53.63, 40.06
and 40.01, 27.65, 22.46 and 22.22, 22.37 and 22.33, 18.45 and 18.32,
17.38 and 17.34, 14.83 and 14.79, 11.25, and 11.24. HRMS (ESI): m/
z calcd for C29H34Cl2N3O
+ [M + H]+, 510.2073; found, 510.2082.
Chiral Separation of Racemic 22e. Analytical conditions:
Chiralpak AY-3 column (15 cm × 4.6 mm), 30% isopropanol and
0.1% diethylamine in n-hexane as the fluent phase, flow rate = 1.0
mL/min, λ = 254 nm. Preparative conditions: Chiralcel AY-5 column
(25 cm × 50 mm, 10 μM), 30% isopropanol and 0.1% diethylamine in
n-hexane as the eluting system, flow rate = 60 mL/min, λ = 254 nm.
(1R,2R)-22e was isolated as the first-eluting peaks (ee = 100%) and
(1S,2S)-22e as the second-eluting peaks (ee = 100%), both of which
appeared as a colorless oil after evaporation. The oil was dissolved in
dichloromethane and stirred with 2 M HCl in diethyl ether (20 mL/
mmol substrate) at room temperature for 15 min, which was then
condensed to dryness to give HCl salts, respectively.
N-(4-((((1R,2R)-2-(5-Fluoro-2-methoxyphenyl)cyclopropyl)-
methyl)(propyl)amino)butyl)-4-(pyridin-2-yl)benzamide Hydro-
chloride ((1R,2R)-22e). White solid. HPLC: 99.1% (λ = 254 nm, tR
= 15.5 min). 1H NMR (800 MHz, CD3OD): δ 8.87 (d, J = 5.7 Hz,
1H), 8.65 (t, J = 7.9 Hz, 1H), 8.40 (d, J = 8.1 Hz, 1H), 8.12 (t, J = 8.1
Hz, 2H), 8.09−8.00 (m, 3H), 6.94−6.91 (m, 1H), 6.90−6.86 (m,
1H), 6.72−6.68 (m, 1H), 3.85 (s, 3H), 3.52−3.47 (m, 2H), 3.39−
3.32 (m, 2H), 3.29−3.25 (m, 1H), 3.24−3.17 (m, 2H), 2.34−2.29
(m, 1H), 1.90−1.83 (m, 2H), 1.82−1.71 (m, 4H), 1.38−1.34 (m,
1H), 1.25−1.20 (m, 1H), 1.11−1.06 (m, 1H), 1.04−1.00 (m, 3H).
13C NMR (201 MHz, CD3OD): δ 168.80, 158.65 (d, JCF = 236.7 Hz),
155.67, 153.39, 147.71, 143.99, 138.69, 135.60, 132.04 (d, JCF = 7.4
Hz), 129.68 (2C), 129.51 (2C), 127.27, 127.03, 113.91 (d, JCF = 23.1
Hz),113.31 and 113.28 (d, JCF = 24.5 Hz), 112.60 (d, JCF = 8.7 Hz),
58.05, 56.63, 55.77 and 55.33, 53.87 and 53.48, 40.09 and 40.06,
27.65, 22.50 and 22.36, 18.47 and 18.31, 18.43 and 18.41, 17.55 and
17.46, 13.51, 11.27, and 11.26. HRMS (ESI): m/z calcd for
C30H37FN3O2





chloride ((1S,2S)-22e). White solid. HPLC: 98.7% (λ = 254 nm, tR
= 15.4 min). 1H NMR (800 MHz, CD3OD): δ 8.88 (d, J = 5.7 Hz,
1H), 8.67 (t, J = 8.0 Hz, 1H), 8.42 (d, J = 8.1 Hz, 1H), 8.15−8.11 (m,
2H), 8.09−8.04 (m, 3H), 6.94−6.91 (m, 1H), 6.90−6.87 (m, 1H),
6.72−6.69 (m, 1H), 3.85 (s, 3H), 3.52−3.47 (m, 2H), 3.39−3.32 (m,
2H), 3.29−3.24 (m, 2H), 3.24−3.18 (m, 2H), 2.35−2.29 (m, 1H),
1.90−1.83 (m, 2H), 1.82−1.71 (m, 4H), 1.38−1.34 (m, 1H), 1.24−
1.21 (m, 1H), 1.10−1.07 (m, 1H), 1.05−1.00 (m, 3H). 13C NMR
(201 MHz, CD3OD): δ 168.75, 158.66 (d, JCF = 236.7 Hz), 155.67,
153.19, 148.12, 143.68, 138.82, 135.23, 132.05 (d, JCF = 7.6 Hz),
129.73 (2C), 129.57 (2C), 127.48, 127.15, 113.91 (d, JCF = 23.1 Hz),
113.31 and 113.28 (d, JCF = 23.9 Hz), 112.59 (d, JCF = 7.5 Hz), 58.04,
56.63, 55.77 and 55.32, 53.87 and 53.48, 40.10 and 40.07, 27.64,
22.50 and 22.37, 18.47 and 18.31, 18.43 and 18.41, 17.55 and 17.46,
13.51, 11.27, and 11.26. HRMS (ESI): m/z calcd for C30H37FN3O2
+
[M + H]+, 490.2864; found, 490.2867. [α]D
20 +11.67 (c 0.6, MeOH).
Chiral Separation of Racemic 30p. Analytical conditions:
Chiralpak AY-3 column (15 cm × 4.6 mm), 10% EtOH and 0.1%
diethylamine in n-hexane as the fluent phase, flow rate = 1.0 mL/min,
λ = 254 nm. Preparative conditions: Chiralcel AY-5 column (25 cm ×
50 mm, 10 μM), 15% EtOH in n-hexane as the eluting system, flow
rate = 60 mL/min, λ = 254 nm. (1R,2R)-30p was isolated as the first-
eluting peaks (ee = 95.1%) and (1S,2S)-30p as the second-eluting
peaks (ee = 97.3%), both of which appeared as a colorless oil after
evaporation. The oil was dissolved in dichloromethane and stirred
with 2 M HCl in diethyl ether (20 mL/mmol substrate) at room




White solid. HPLC: 98.1% (λ = 254 nm, tR = 27.1 min).
1H NMR
(800 MHz, CD3OD): δ 8.38 (d, J = 11.3 Hz, 1H), 7.98−7.91 (m,
3H), 7.90−7.86 (m, 1H), 7.62−7.56 (m, 2H), 7.37 (d, J = 8.0 Hz,
1H), 7.21−7.18 (m, 1H), 7.05 (d, J = 7.8 Hz, 1H), 3.62−3.57 (m,
1H), 3.55−3.50 (m, 2H), 3.41−3.33 (m, 2H), 3.27−3.16 (m, 3H),
2.35−2.31 (m, 1H), 1.92−1.83 (m, 2H), 1.82−1.73 (m, 4H), 1.47−
1.43 (m, 1H), 1.29−1.25 (m, 1H), 1.25−1.21 (m, 1H), 1.04−1.00
(m, 3H). 13C NMR (201 MHz, CD3OD): δ 170.36, 141.89, 136.28,
134.19 and 134.17, 134.04, 133.93, 132.67 and 136.66, 130.01,
129.68, 129.39, 128.92, 128.91, 128.80, 128.78, 127.90, 126.60 and
126.56, 124.79, 57.88 and 57.84, 55.90 and 55.64, 53.98 and 53.67,
39.87 and 39.80, 27.78, 22.41 and 22.37, 22.27 and 22.14, 18.46 and
18.31, 17.35 and 17.32, 14.80 and 14.72, 11.22, and 11.21. HRMS
(ESI): m/z calcd for C28H33Cl2N2O
+ [M + H]+, 483.1964; found,
483.1957. [α]D
20 −2.50 (c 0.4, MeOH).
N-(4-((((1S,2S)-2-(2,3-Dichlorophenyl)cyclopropyl)methyl)-
(propyl)amino)butyl)-2-naphthamide Hydrochloride ((1S,2S)-30p).
White solid. HPLC: 96.0% (λ = 254 nm, tR = 27.0 min).
1H NMR
(800 MHz, CD3OD): δ 8.38 (d, J = 11.4 Hz, 1H), 7.99−7.91 (m,
3H), 7.90−7.86 (m, 1H), 7.61−7.56 (m, 2H), 7.37 (d, J = 8.0 Hz,
1H), 7.21−7.17 (m, 1H), 7.05 (d, J = 7.9 Hz, 1H), 3.62−3.56 (m,
1H), 3.55−3.48 (m, 2H), 3.39−3.31 (m, 2H), 3.26−3.16 (m, 3H),
2.37−2.31 (m, 1H), 1.92−1.84 (m, 2H), 1.82−1.74 (m, 4H), 1.49−
1.44 (m, 1H), 1.28−1.25 (m, 1H), 1.24−1.22 (m, 1H), 1.05−1.00
(m, 3H). 13C NMR (201 MHz, CD3OD): δ 170.33, 141.87, 136.27,
134.18 and 134.16, 134.03, 133.92, 132.67 and 132.66, 130.01,
129.66, 129.38, 128.91, 128.89, 128.79, 128.78, 127.89, 126.60 and
126.55, 124.80, 57.87 and 57.83, 55.88 and 55.62, 53.97 and 53.66,
39.88 and 39.81, 27.76, 22.41 and 22.36, 22.27 and 22.15, 18.44 and
18.30, 17.34 and 17.31, 14.81 and 14.73, 11.22. HRMS (ESI): m/z
calcd for C28H33Cl2N2O
+ [M + H]+, 483.1964; found, 483.1961. [α]D
20
+1.94 (c 0.6, MeOH).
Chiral separation of racemic 30q. Analytical conditions:
Chiralcel OJ-H column (25 cm × 4.6 mm), 10% isopropanol and
0.1% diethylamine in n-hexane as the fluent phase, flow rate = 1.0
mL/min, λ = 214 nm. Preparative conditions: Chiralcel OJ-5A
column (25 cm × 50 mm, 10 μM), 1% isopropanol and 0.1%
diethylamine in n-hexane as the eluting system, flow rate = 60 mL/
min, λ = 220 nm. (1R,2R)-30q was isolated as the first-eluting peaks
(ee = 98.6%) and (1S,2S)-30q as the second-eluting peaks (ee =
97.4%), both of which appeared as a colorless oil after evaporation.
The oil was dissolved in dichloromethane and stirred with 2 M HCl in
diethyl ether (20 mL/mmol substrate) at room temperature for 15




((1R,2R)-30q). White solid. HPLC: 97.5% (λ = 280 nm, tR = 22.5
min). 1H NMR (800 MHz, CD3OD): δ 7.60 (d, J = 8.0 Hz, 1H), 7.44
(d, J = 8.3 Hz, 1H), 7.36 (dt, J = 8.0, 1.5 Hz, 1H), 7.23−7.21 (m,
1H), 7.17 (td, J = 7.9, 3.5 Hz, 1H), 7.09−7.05 (m, 2H), 7.02 (dt, J =
7.8, 1.8 Hz, 1H), 3.59−3.54 (m, 1H), 3.50−3.45 (m, 2H), 3.37−3.28
(m, 2H), 3.23−3.15 (m, 3H), 2.34−2.30 (m, 1H), 1.89−1.82 (m,
2H), 1.81−1.71 (m, 4H), 1.47−1.41 (m, 1H), 1.26−1.23 (m, 1H),
1.23−1.20 (m, 1H), 1.02−0.99 (m, 3H). 13C NMR (201 MHz,
CD3OD): δ 164.33, 141.86, 138.29, 134.15, 133.91, 132.06, 129.65
and 129.64, 128.96, 128.91, 126.56 and 126.53, 125.12, 122.77,
121.23, 113.09, 104.54, 57.85, 55.84 and 55.62, 53.94 and 53.66,
39.34 and 39.31, 27.81 and 27.79, 22.39 and 22.32, 22.24 and 22.19,
18.43 and 18.28, 17.34 and 17.30, 14.79 and 14.73, 11.21, and 11.20.
HRMS (ESI): m/z calcd for C26H32Cl2N3O
+ [M + H]+, 472.1917;
found, 472.1921. [α]D
20 −0.25 (c 0.4, MeOH).
N-(4-((((1S,2S)-2-(2,3-Dichlorophenyl)cyclopropyl)methyl)-
(propyl)amino)butyl)-1H-indole-2-carboxamide Hydrochloride
((1S,2S)-30q). White solid. HPLC: 97.8% (λ = 280 nm, tR = 22.8
min). 1H NMR (800 MHz, CD3OD): δ 7.60 (d, J = 8.0 Hz, 1H), 7.44
(d, J = 8.3 Hz, 1H), 7.38−7.35 (m, 1H), 7.23−7.20 (m, 1H), 7.17 (td,
J = 7.9, 3.6 Hz, 1H), 7.08−7.05 (m, 2H), 7.04−7.02 (m, 1H), 3.59−
3.55 (m, 1H), 3.50−3.46 (m, 2H), 3.37−3.29 (m, 2H), 3.25−3.15
(m, 3H), 2.34−2.30 (m, 1H), 1.90−1.82 (m, 2H), 1.81−1.70 (m,
4H), 1.47−1.41 (m, 1H), 1.26−1.23 (m, 1H), 1.23−1.20 (m, 1H),
1.02−0.98 (m, 3H). 13C NMR (201 MHz, CD3OD): δ 164.35,
141.87, 138.30, 134.16, 133.92, 132.06, 129.65, 128.97, 128.92,
126.56 and 126.54, 125.12, 122.76, 121.22, 113.09, 104.52, 57.86,
55.85 and 55.64, 53.95 and 55.66, 39.34 and 39.31, 27.82 and 27.81,
22.39 and 22.33, 22.25 and 22.20, 18.44 and 18.29, 17.35 and 17.31,
14.79 and 14.72, 11.20, and 11.19. HRMS (ESI): m/z calcd for
C26H32Cl2N3O
+ [M + H]+, 472.1917; found, 472.1926. [α]D
20 +0.17 (c
0.6, MeOH).
Chiral Separation of Racemic 30r. Analytical conditions:
Chiralcel OD-H column (15 cm × 4.6 mm), 15% isopropanol and
0.1% diethylamine in n-hexane as the fluent phase, flow rate = 1.0
mL/min, λ = 254 nm. Preparative conditions: Chiralcel OD-5 column
(25 cm × 50 mm, 10 μM), 20% isopropanol and 0.1% diethylamine in
n-hexane as the eluting system, flow rate = 60 mL/min, λ = 254 nm.
(1R,2R)-30r was isolated as the first-eluting peaks (ee = 99.4%) and
(1S,2S)-30r as the second-eluting peaks (ee = 99.4%), both of which
appeared as a colorless oil after evaporation. Both enantiomers were
dissolved in dichloromethane and stirred with 2 M HCl in diethyl
ether (20 mL/mmol substrate) at room temperature for 15 min and
then condensed to dryness to give the corresponding HCl salts.
N-(4-((((1R,2R)-2-(2,3-Dichlorophenyl)cyclopropyl)methyl)-
(propyl)amino)butyl)-4-(pyridin-2-yl)benzamide Hydrochloride
((1R,2R)-30r). White solid. HPLC: 98.4% (λ = 254 nm, tR = 18.28
min). 1H NMR (800 MHz, CD3OD): δ 8.88 (d, J = 5.8 Hz, 1H), 8.68
(t, J = 7.9 Hz, 1H), 8.43 (d, J = 8.1 Hz, 1H), 8.15−8.11 (m, 2H),
8.09−8.05 (m, 3H), 7.42−7.38 (m, 1H), 7.24 (t, J = 7.9 Hz, 1H),
7.11−7.09 (m, 1H), 3.61−3.56 (m, 1H), 3.53−3.47 (m, 2H), 3.40−
3.32 (m, 2H), 3.29−3.18 (m, 3H), 2.39−2.33 (m, 1H), 1.93−1.84
(m, 2H), 1.83−1.72 (m, 4H), 1.53−1.46 (m, 1H), 1.30−1.25 (m,
2H), 1.06−1.02 (m, 3H). 13C NMR (201 MHz, CD3OD): δ 168.72,
153.07, 148.32, 143.53, 141.98, 138.87, 135.04, 134.15, 133.87,
129.75, and 129.74 (2C), 129.66 and 129.64, 129.60, and 129.59
(2C), 128.97 and 128.87, 127.57, 127.21 and 126.94, 126.66 and
126.61, 57.83 and 57.79, 55.85 and 55.56, 53.92 and 53.62, 40.06 and
40.01, 27.62, 22.45 and 22.22, 22.36 and 22.33, 18.44 and 18.31,
17.39 and 17.35, 14.87 and 14.83, 11.27. HRMS (ESI): m/z calcd for
C29H34Cl2N3O





((1S,2S)-30r). White solid. HPLC: 97.3% (λ = 254 nm, tR = 18.4
min). 1H NMR (800 MHz, CD3OD): δ 8.88 (d, J = 5.8 Hz, 1H), 8.68
(t, J = 7.9 Hz, 1H), 8.42 (d, J = 8.1 Hz, 1H), 8.15−8.11 (m, 2H),
8.09−8.04 (m, 3H), 7.39 (d, J = 8.0 Hz, 1H), 7.24 (t, J = 7.9 Hz, 1H),
7.11−7.08 (m, 1H), 3.62−3.57 (m, 1H), 3.54−3.48 (m, 2H), 3.40−
3.32 (m, 2H), 3.29−3.18 (m, 3H), 2.38−2.34 (m, 1H), 1.91−1.84
(m, 2H), 1.83−1.74 (m, 4H), 1.52−1.47 (m, 1H), 1.32−1.24 (m,
2H), 1.07−1.00 (m, 3H). 13C NMR (201 MHz, CD3OD): δ 168.77,
153.20, 148.13, 143.68, 141.98, 138.82, 135.23, 134.16, 133.91,
129.73, and 129.72 (2C), 129.67, 129.58, and 129.57 (2C), 128.98,
127.49, 127.16, 126.66 and 126.61, 57.85 and 57.80, 55.87 and 55.58,
53.94 and 53.64, 40.05 and 40.00, 27.64, 22.46 and 22.22, 22.37 and
22.33, 18.45 and 18.32, 17.40 and 17.34, 14.85 and 14.81, 11.26, and
11.25. HRMS (ESI): m/z calcd for C29H34Cl2N3O
+ [M + H]+,
510.2073; found, 510.2081. [α]D
20 +2.87 (c 0.5, MeOH).
Chiral Separation of Racemic 13c. Analytical conditions:
Chiralcel OJ-H column (25 cm × 4.6 mm), 1% EtOH in n-hexane
as the fluent phase, flow rate = 1.0 mL/min, λ = 280 nm. Preparative
conditions: Chiralcel OJ-5A column (25 cm × 50 mm, 10 μM), 1%
EtOH in n-hexane as the eluting system, flow rate = 60 mL/min, λ =
214 nm). (+)-13c was isolated as the first-eluting peaks and (−)-13c
as the second-eluting peaks, both after evaporation appeared as
colorless oil, and ee > 95%.
(+)-tert-Butyl (((1R,2R)-2-(5-fluoro-2-methoxyphenyl)-
cyclopropyl)methyl)-carbamate ((+)-13c). Ee: 98.5%. 1H NMR
(800 MHz, CDCl3): δ 6.84 (td, J = 8.4, 3.1 Hz, 1H), 6.75 (dd, J = 8.9,
4.5 Hz, 1H), 6.64 (dd, J = 9.2, 3.1 Hz, 1H), 3.88 (s, 3H), 3.55 (d, J =
13.0 Hz, 1H), 2.72 (dd, J = 13.1, 8.7 Hz, 1H), 1.85−1.81 (m, 1H),
1.47 (s, 9H), 1.05−0.98 (m, 2H), 0.88−0.83 (m, 1H). [α]D20 +10.93 (c
0.5, CHCl3).
(− )-tert-Butyl( ( (1S,2S)-2-(5-fluoro-2-methoxyphenyl)-
cyclopropyl)methyl)-carbamate ((−)-13c). Ee: 96.4%. 1H NMR
(800 MHz, CDCl3): δ 6.84 (td, J = 8.5, 3.1 Hz, 1H), 6.75 (dd, J = 8.9,
4.5 Hz, 1H), 6.64 (dd, J = 9.2, 3.1 Hz, 1H), 3.89 (s, 3H), 3.55 (d, J =
12.8 Hz, 1H), 2.72 (dd, J = 13.1, 8.6 Hz, 1H), 1.85−1.81 (m, 1H),
1.47 (s, 9H), 1.05−0.98 (m, 2H), 0.88−0.83 (m, 1H). [α]D20 −11.13
(c 0.5, CHCl3).
(−)-((1R,2R)-2-(5-Fluoro-2-methoxyphenyl)cyclopropyl)-
methanamine Hydrochloride ((−)-14c). Compound (+)-13c (378
mg, 1.28 mmol) was dissolved in 4 M HCl (g) in dioxane (20 mL)
and stirred at room temperature overnight. The solvent was
evaporated, and the residue was suspended in a mixture of ethyl
acetate and petroleum ether (v/v = 1/2, 10 mL) for 10 min. The
precipitate was collected by filtration, washed with ethyl acetate (3
mL), and dried under a vacuum to give the title compound as a yellow
solid (290 mg, 98%). 1H NMR (800 MHz, CD3OD): δ 6.93−6.86
(m, 2H), 6.72 (dd, J = 9.4, 2.9 Hz, 1H), 3.86 (s, 3H), 3.07 (dd, J =
13.1, 7.1 Hz, 1H), 2.93 (dd, J = 13.1, 8.0 Hz, 1H), 2.14−2.10 (m,
1H), 1.28−1.23 (m, 1H), 1.14−1.10 (m, 1H), 1.04−0.99 (m, 1H).
HRMS (ESI): m/z calcd for C11H15FNO
+ [M + H]+, 196.1132;
found, 196.1128. [α]D
20 −14.80 (c 0.5, MeOH).
(+)-((1S,2S)-2-(5-Fluoro-2-methoxyphenyl)cyclopropyl)-
methanamine Hydrochloride ((+)-14c). The title compound was
prepared from (−)-13c as described for (−)-14c as a yellow solid. 1H
NMR (800 MHz, CD3OD): δ 6.92−6.87 (m, 2H), 6.72 (dd, J = 9.4,
2.9 Hz, 1H), 3.86 (s, 3H), 3.07 (dd, J = 13.0, 7.1 Hz, 1H), 2.93 (dd, J
= 13.0, 8.0 Hz, 1H), 2.14−2.08 (m, 1H), 1.28−1.23 (m, 1H), 1.14−
1.08 (m, 1H), 1.05−0.99 (m, 1H). HRMS (ESI): m/z calcd for
C11H15FNO




methyl)propan-1-amine ((−)-21c). The title compound was
prepared from (−)-14c as described for 21a as a colorless oil.
HRMS (ESI): m/z calcd for C14H21FNO
+ [M + H]+, 238.1602;
found, 238.1603. [α]D
20 −14.60 (c 0.5, MeOH).
(+)-N-(((1S,2S)-2-(5-Fluoro-2-methoxyphenyl)cyclopropyl)-
methyl)propan-1-amine ((+)-21c). The title compound was
prepared from (+)-14c as described for 21a as a colorless oil.
HRMS (ESI): m/z calcd for C14H21FNO
+ [M + H]+, 238.1602;
found, 238.1605. [α]D
20 +16.13 (c 0.5, MeOH).
(−)-N-(4-((((1R,2R)-2-(5-Fluoro-2-methoxyphenyl)cyclopropyl)-
methyl)(propyl)amino)butyl)-4-(pyridin-2-yl)benzamide Hydro-
chloride ((−)-22e). A mixture of (−)-21c (41 mg, 0.17 mmol) and
20c (46 mg, 0.17 mmol) in THF (15 mL) was stirred at room
temperature for 15 min. NaHB(AcO)3 (73 mg, 0.35 mmol) was
added, and the reaction mixture was stirred at room temperature
overnight. Water was added, and the mixture was extracted with ethyl
acetate. The combined extracts were washed with brine and
concentrated, and the residue was purified by flash chromatography
(0−5% methanol in dichloromethane) to give a colorless oil (28 mg,
33%), which was converted into the HCl salt using a similar method
as depicted for 17a. 1H NMR (800 MHz, CD3OD): δ 8.86 (d, J = 5.8
Hz, 1H), 8.62 (t, J = 7.9 Hz, 1H), 8.38 (d, J = 8.1 Hz, 1H), 8.14−8.10
(m, 2H), 8.09−8.06 (m, 2H), 8.03−8.00 (m, 1H), 6.93−6.91 (m,
1H), 6.90−6.86 (m, 1H), 6.72−6.68 (m, 1H), 3.85 (s, 3H), 3.52−
3.47 (m, 2H), 3.41−3.32 (m, 2H), 3.30−3.16 (m, 4H), 2.35−2.29
(m, 1H), 1.90−1.83 (m, 2H), 1.83−1.72 (m, 4H), 1.39−1.33 (m,
1H), 1.25−1.21 (m, 1H), 1.10−1.07 (m, 1H), 1.05−1.00 (m, 3H).
13C NMR (201 MHz, CD3OD): δ 168.80, 158.65 (d, JCF = 236.9 Hz),
155.67, 153.45, 147.55, 144.11, 138.63, 135.72, 132.05 (d, JCF = 7.5
Hz), 129.67 and 129.66 (2C), 129.48 (2C), 127.18, 126.97, 113.90
(d, JCF = 22.8 Hz), 113.31 and 113.28 (d, JCF = 24.3 Hz), 112.58 (d,
JCF = 8.6 Hz), 58.04, 56.64, 55.76 and 55.32, 53.87 and 53.47, 40.09
and 40.05, 27.65, 22.49 and 22.36, 18.46 and 18.31, 18.43 and 18.41,
17.55 and 17.46, 13.52, 11.27, and 11.26. HRMS (ESI): m/z calcd for
C30H37FN3O2





chloride ((+)-22e). The title compound was prepared from (+)-21c
using the same method as described for (−)-22e. 1H NMR (800
MHz, CD3OD): δ 8.88 (d, J = 5.8 Hz, 1H), 8.66 (t, J = 7.9 Hz, 1H),
8.41 (d, J = 8.1 Hz, 1H), 8.14−8.11 (m, 2H), 8.09−8.03 (m, 3H),
6.94−6.91 (m, 1H), 6.90−6.86 (m, 1H), 6.72−6.69 (m, 1H), 3.85 (s,
3H), 3.53−3.47 (m, 2H), 3.41−3.32 (m, 2H), 3.30−3.18 (m, 4H),
2.34−2.30 (m, 1H), 1.89−1.83 (m, 2H), 1.83−1.72 (m, 4H), 1.39−
1.32 (m, 1H), 1.25−1.21 (m, 1H), 1.10−1.06 (m, 1H), 1.05−0.99
(m, 3H). 13C NMR (201 MHz, CD3OD): δ 168.75, 158.65 (d, JCF =
237.0 Hz), 155.67, 153.18, 148.14, 143.66, 138.83, 135.21, 132.05 (d,
JCF = 7.3 Hz), 129.73 and 129.72 (2C), 129.58 (2C), 127.50, 127.16,
113.91 (d, JCF = 22.7 Hz), 113.31 and 113.28 (d, JCF = 24.2 Hz),
112.60 (d, JCF = 8.4 Hz), 58.05, 56.64, 55.77 and 55.33, 53.87 and
53.48, 40.10 and 40.07, 27.65, 22.50 and 22.37, 18.47 and 18.31,
18.43 and 18.41, 17.55 and 17.46, 13.52, 11.27, and 11.26. HRMS
(ESI): m/z calcd for C30H37FN3O2
+ [M + H]+, 490.2864; found,
490.2859. [α]D
20 +11.80 (c 0.5, MeOH).
Radioligand Binding Assays. Radioligand binding affinities were
determined by the National Institute of Mental Health Psychoactive
Drug Screening Program (NIMH PDSP), directed by Bryan L Roth,
M.D., Ph.D., the University of North Carolina at Chapel Hill, North
Carolina, and Program Officer Jamie Driscoll at NIMH, Bethesda,
MD. Detail binding protocols and assay conditions are also available
at https://pdspdb.unc.edu/pdspWeb/?site=assays.
D3 GloSensor cAMP Assays. Human D3 and GloSensor cAMP
plasmids (Promega) were cotransfected (4 μg receptor DNA and 4 μg
GloSensor cAMP reporter DNA for a 10 cm dish, increased
proportionally if using a larger size of dishes) in HEK293 T cells
overnight in full growth medium (DMEM + 10% FBS) and plated in
poly-L-Lys-coated 384-well white assay plates using DMEM
containing 1% dialyzed FBS at a density of 15 000−20 000 cells per
40 μL/well. After a minimum of 6 h recovery (up to 24 h), cells were
removed from the medium, stimulated with 25 μL/well drug solutions
prepared in assay buffer (1× HBSS, 20 mM HEPES, pH 7.4, 0.1%
BSA) for 15 min, followed by the addition of 10 μL/well of the
mixture of 2 mM luciferin and 100 nM isoproterenol (final), all at
room temperature. For antagonist assays, 10 nM dopamine (final) was
added at 10 min after test compounds. Luminescence was counted
after 20 min of incubation. Agonist EC50 or antagonist Ki values were
shown as the mean from at least three individual experiments.
GPCR Tango (β-Arrestin2 Recruitment) Assays. GPCR Tango
assays are conducted as described previously.27 In brief, HTLA cells,
stably expressing a β-arrestin2-TEV fusion protein and a tTA-
dependent luciferase reporter, were transiently transfected (8 μg
receptor DNA per 10 cm dish) in full growth medium (DMEM with
10% FBS) and plated in poly-L-Lys-coated 384-well white assay plates
in DMEM with 1% dialyzed FBS at a density of 10 000−15 000 cells/
well in a total of 40 μL. After a minimum of 3 h of recovery, drug
dilutions were made in DMEM with 1% dFBS at 5× of the final
concentrations for agonist assays and added to cells at 10 μL/well for
incubation (around 16 h). Medium and drugs were removed, and
Bright-Glo reagents (Promega) were added. Luminescence was
counted on a luminescence counter after 20 min of incubation at
room temperature. Results (relative luminescence counts) were
analyzed in Prism 7.0. EC50 or % activation values were shown as
the mean from at least three individual experiments.
5-HT2C Calcium Mobilization Assays. HEK293 cells stably
expressing 5-HT2C receptors were plated in poly-L-Lys-coated 384-
well black assay plates in DMEM containing 1% dialyzed FBS
overnight at a density of 15 000 cells/well/40 μL and incubated
overnight. Cells were removed from the medium and loaded with
Calcium dye (Fluo-4 Direct, Invitrogen), 20 μL/well, prepared in
assay buffer (1× HBSS, 20 mM HEPES, pH 7.4, 2.5 mM probenecid),
for 50 min in the cell culture incubator (37 °C), followed by 10 min
of incubation at room temperature in the dark (to equilibrate to room
temperature). Drug solutions (at 3× of the final concentrations) were
prepared in assay buffer and aliquoted in a matching 384-well plate. A
cell plate and a drug plate were both then loaded into the FLIPRTETRA
(Molecular Devices). A FLIPR protocol was designed to transfer 10
μL/well drug solutions into the cell plate, and fluorescence was read
for a total of 2 min at a rate of 1 read per second, including 10 s before
drug addition. The initial 10 readings served as the background for
each well, and the average background was subtracted from the
maximum reading within 60 s after drug addition. Fluorescence
intensity (fold of basal) upon drug stimulation was exported and
analyzed in Prism 7.0. For antagonist assays, an additional 10 μL of 5-
HT (final of 1 nM) was added 15 min after the first drug addition,
and fluorescence intensity (fold of basal) was exported and analyzed
as above. EC50 or IC50 values were shown as the mean from at least
three individual experiments.
Computational Methods. Molecular dockings were performed
using modules (Maestro, Ligprep, Protein Preparation Wizard, and
Glide) in the Schrödinger software package (Release 2017−4). The
crystal structures of antagonist-bound D3R (PDB code: 3PBL)21 and
agonist- and antagonist-bound 5HT2C (PDB codes: 6BQG and
6BQH)20 were retrieved from the Protein Data Bank. The missing
side chains and hydrogen bonds were fixed and optimized using the
Protein Preparation Wizard.28 All ligands were prepared using
LigPrep with default settings. The docking grid was prepared with
Glide defining the binding site by crystal ligands and setting the ligand
diameter midpoint box to 10 Å on all three axes, while the hydroxyl
groups in Ser, Thr, and Tyr and the thiol group in Cys around the
pocket were allowed to rotate through the “Rotatable Groups” option.
Finally, all of these ligands were docked into the calculated receptor
grid using the XP scoring function and enhanced sampling. The
docked results were visualized and analyzed in Maestro, and the best
scoring poses were selected. All residues within 5 Å of the docked
ligands were subjected to relax with the sampling method “Minimize”
in the Prime MM-GBSA module,29 which were then rescored by
Glide XP. Finally, by visual inspection of the optimized docking pose
and considering the XP docking scores, the predicted binding poses of
these ligands were obtained.
PK and Brain Penetration Studies. Studies were performed by
Suzhou Kangrun Pharmaceutical Testing Service, Inc. (Suzhou,
China). Male ICR mice (age 6−8 weeks, ∼25 g body weight) were
purchased from JOINN Laboratories, Inc. (Suzhou). For PK studies,
compounds were dissolved in saline and administered at doses of 5
mg/kg (iv) and 10 mg/kg (po), respectively, with nine animals in
each group. Blood samples (0.1 mL) were collected from mouse orbit
at 0, 0.083, 0.25, 0.5, 1, 2, 4, 6, 8, and 24 h, which were then
centrifuged at 5000 rpm at 4 °C for 10 min to collect plasma samples.
Brain tissues were collected at 0.5 and 2.0 h, which were washed with
saline, weighed, and homogenated in 50% cold methanol (brain
weight (g)/50% methanol (mL) = 1/3) to obtain drug solutions. All
samples were stored at −80 °C before analysis. Drug concentrations
in the samples were determined using liquid chromatography−mass
spectrometry (LC−MS/MS). All studies were performed with




The Supporting Information is available free of charge at
https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01835.
Binding pKi ± SEM values; 5-HT2A and 5-HT2B activity
of selected compounds; binding affinities of (1R,2R)-22e





5-HT2C (active) + ergotamine (PDB)
5-HT2C (active) + compound 2 (PDB)
5-HT2C (inactive) + ritanserin (PDB)
5-HT2C (inactive) + (1S,2S)-22e (PDB)
■ AUTHOR INFORMATION
Corresponding Authors
Xi-Ping Huang − Department of Pharmacology, National
Institute of Mental Health Psychoactive Drug Screening
Program (NIMH PDSP), University of North Carolina Chapel
Hill Medical School, Chapel Hill, North Carolina 27599,
United States; Email: xphuang@unc.edu
Jianjun Cheng − iHuman Institute, ShanghaiTech University,
Shanghai 201210, China; orcid.org/0000-0001-6065-
2682; Email: chengjj@shanghaitech.edu.cn
Authors
Liang Tan − iHuman Institute, ShanghaiTech University,
Shanghai 201210, China
Qingtong Zhou − iHuman Institute, ShanghaiTech University,
Shanghai 201210, China; orcid.org/0000-0001-8124-
3079
Wenzhong Yan − iHuman Institute, ShanghaiTech University,
Shanghai 201210, China
Jian Sun − iHuman Institute, ShanghaiTech University,
Shanghai 201210, China
Alan P. Kozikowski − StarWise Therapeutics LLC, Chicago,
Illinois 60614, United States
Suwen Zhao − iHuman Institute and School of Life Science and
Technology, ShanghaiTech University, Shanghai 201210,
China; orcid.org/0000-0001-5609-434X
Complete contact information is available at:
https://pubs.acs.org/10.1021/acs.jmedchem.9b01835
Author Contributions
∥L.T. and Q.Z. contributed equally.
Notes
The authors declare no competing financial interest.
■ ACKNOWLEDGMENTS
J.C. and S.Z. are thankful to the Shanghai Municipal
Government, ShanghaiTech University, for startup financial
support. This work is supported by the National Natural
Science Foundation of China (81703361 to J.C., 31971178 to
S.Z., and 21704064 to Q.Z.) and the National Key R&D
Program of China (2018YFA0507000 to S.Z.). We thank the
National Institute of Mental Health Psychoactive Drug
Screening Program (NIMH PDSP) directed by B. L. Roth
for conducting radioligand binding assays, J. Zhang and L.
Yang for NMR data collection, and F. Zhao for LC−MS data
collection. We thank R.C. Stevens, Z.-J. Liu, G. Zhong, H. Tao,
C. Zhang, and Y. Xu for their helpful discussions and support.
■ ABBREVIATIONS USED
cAMP, cyclic adenosine monophosphate; CNS, central
nervous system; EBP, extended binding pocket; FDA, Food
and Drug Administration; GPCRs, G protein-coupled
receptors; HPLC, high-performance liquid chromatography;
OBP, orthosteric binding pocket; PCPMA, 2-phenylcyclopro-
pylmethylamine; PDB, Protein Data Bank; PK, pharmacoki-
netic; SAR, structure−activity relationship
■ REFERENCES
(1) Lagerstrom, M. C.; Schioth, H. B. Structural Diversity of G
Protein-Coupled Receptors and Significance for Drug Discovery. Nat.
Rev. Drug Discovery 2008, 7, 339−357.
(2) Hauser, A. S.; Attwood, M. M.; Rask-Andersen, M.; Schioth, H.
B.; Gloriam, D. E. Trends in GPCR Drug Discovery: New Agents,
Targets and Indications. Nat. Rev. Drug Discovery 2017, 16, 829−842.
(3) Vass, M.; Podlewska, S.; de Esch, I. J. P.; Bojarski, A. J.; Leurs,
R.; Kooistra, A. J.; de Graaf, C. Aminergic GPCR-Ligand Interactions:
A Chemical and Structural Map of Receptor Mutation Data. J. Med.
Chem. 2019, 62, 3784−3839.
(4) Cheng, J.; Giguere, P. M.; Onajole, O. K.; Lv, W.; Gaisin, A.;
Gunosewoyo, H.; Schmerberg, C. M.; Pogorelov, V. M.; Rodriguiz, R.
M.; Vistoli, G.; Wetsel, W. C.; Roth, B. L.; Kozikowski, A. P.
Optimization of 2-Phenylcyclopropylmethylamines as Selective
Serotonin 2C Receptor Agonists and Their Evaluation as Potential
Antipsychotic Agents. J. Med. Chem. 2015, 58, 1992−2002.
(5) Cheng, J.; Giguere, P. M.; Schmerberg, C. M.; Pogorelov, V. M.;
Rodriguiz, R. M.; Huang, X. P.; Zhu, H.; McCorvy, J. D.; Wetsel, W.
C.; Roth, B. L.; Kozikowski, A. P. Further Advances in Optimizing (2-
Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists:
Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition
Models. J. Med. Chem. 2016, 59, 578−591.
(6) Cheng, J.; McCorvy, J. D.; Giguere, P. M.; Zhu, H.; Kenakin, T.;
Roth, B. L.; Kozikowski, A. P. Design and Discovery of Functionally
Selective Serotonin 2C (5-HT2c) Receptor Agonists. J. Med. Chem.
2016, 59, 9866−9880.
(7) Zhang, G.; Cheng, J.; McCorvy, J. D.; Lorello, P. J.; Caldarone,
B. J.; Roth, B. L.; Kozikowski, A. P. Discovery of N-Substituted 2-
Phenylcyclopropylmethylamines as Functionally Selective Serotonin
2C (5-HT2C) Receptor Agonists for Potential Use as Antipsychotic
Medications. J. Med. Chem. 2017, 60, 6273−6288.
(8) Cheng, J.; Kozikowski, A. P. We Need 2C but Not 2B:
Developing Serotonin 2C (5-HT2C) Receptor Agonists for the
Treatment of CNS Disorders. ChemMedChem 2015, 10, 1963−1967.
(9) Pogorelov, V. M.; Rodriguiz, R. M.; Cheng, J.; Huang, M.;
Schmerberg, C. M.; Meltzer, H. Y.; Roth, B. L.; Kozikowski, A. P.;
Wetsel, W. C. 5-HT2C Agonists Modulate Schizophrenia-Like
Behaviors in Mice. Neuropsychopharmacology 2017, 42, 2163−2177.
(10) Leggio, G. M.; Bucolo, C.; Platania, C. B. M.; Salomone, S.;
Drago, F. Current Drug Treatments Targeting Dopamine D3
Receptor. Pharmacol. Ther. 2016, 165, 164−177.
(11) Pilla, M.; Perachon, S.; Sautel, F.; Garrido, F.; Mann, A.;
Wermuth, C. G.; Schwartz, J. C.; Everitt, B. J.; Sokoloff, P. Selective
Inhibition of Cocaine-Seeking Behaviour by a Partial Dopamine D3
Receptor Agonist. Nature 1999, 400, 371−375.
(12) Newman, A. H.; Battiti, F. O.; Bonifazi, A. 2016 Philip S.
Portoghese Medicinal Chemistry Lectureship: Designing Bivalent or
Bitopic Molecules for G-Protein Coupled Receptors. The Whole Is
Greater Than the Sum of Its Parts. J. Med. Chem. 2020, 63, 1779−
1797.
(13) Tu, Z. D.; Li, S. H.; Cui, J. Q.; Xu, J. B.; Taylor, M.; Ho, D.;
Luedtke, R. R.; Mach, R. H. Synthesis and Pharmacological
Evaluation of Fluorine-Containing D3 Dopamine Receptor Ligands.
J. Med. Chem. 2011, 54, 1555−1564.
(14) Micheli, F.; Arista, L.; Bonanomi, G.; Blaney, F. E.; Braggio, S.;
Capelli, A. M.; Checchia, A.; Damiani, F.; Di-Fabio, R.; Fontana, S.;
Gentile, G.; Griffante, C.; Hamprecht, D.; Marchioro, C.; Mugnaini,
M.; Piner, J.; Ratti, E.; Tedesco, G.; Tarsi, L.; Terreni, S.; Worby, A.;
Ashby, C. R.; Heidbreder, C. 1,2,4-Triazolyl Azabicyclo[3.1.0]-
hexanes: A New Series of Potent and Selective Dopamine D3
Receptor Antagonists. J. Med. Chem. 2010, 53, 374−391.
(15) Micheli, F.; Bacchi, A.; Braggio, S.; Castelletti, L.; Cavallini, P.;
Cavanni, P.; Cremonesi, S.; Dal Cin, M.; Feriani, A.; Gehanne, S.;
Kajbaf, M.; Marchio, L.; Nola, S.; Oliosi, B.; Pellacani, A.; Perdona, E.;
Sava, A.; Semeraro, T.; Tarsi, L.; Tomelleri, S.; Wong, A.; Visentini,
F.; Zonzini, L.; Heidbreder, C. 1,2,4-Triazolyl 5-Azaspiro[2.4]-
heptanes: Lead Identification and Early Lead Optimization of a
New Series of Potent and Selective Dopamine D3 Receptor
Antagonists. J. Med. Chem. 2016, 59, 8549−8576.
(16) Chen, J. Y.; Levant, B.; Jiang, C.; Keck, T. M.; Newman, A. H.;
Wang, S. M. Tranylcypromine Substituted cis-Hydroxycyclobutyl-
naphthamides as Potent and Selective Dopamine D3 Receptor
Antagonists. J. Med. Chem. 2014, 57, 4962−4968.
(17) Battiti, F. O.; Cemaj, S. L.; Guerrero, A. M.; Shaik, A. B.; Lam,
J.; Rais, R.; Slusher, B. S.; Deschamps, J. R.; Imler, G. H.; Newman, A.
H.; Bonifazi, A. The Significance of Chirality in Drug Design and
Synthesis of Bitopic Ligands as D3 Receptor (D3R) Selective
Agonists. J. Med. Chem. 2019, 62, 6287−6314.
(18) Keck, T. M.; John, W. S.; Czoty, P. W.; Nader, M. A.; Newman,
A. H. Identifying Medication Targets for Psychostimulant Addiction:
Unraveling the Dopamine D3 Receptor Hypothesis. J. Med. Chem.
2015, 58, 5361−5380.
(19) Appel, N. M.; Li, S.-H.; Holmes, T. H.; Acri, J. B. Dopamine D3
Receptor Antagonist (GSK598809) Potentiates the Hypertensive
Effects of Cocaine in Conscious, Freely-Moving Dogs. J. Pharmacol.
Exp. Ther. 2015, 354, 484−492.
(20) Peng, Y.; McCorvy, J. D.; Harpsoe, K.; Lansu, K.; Yuan, S.;
Popov, P.; Qu, L.; Pu, M.; Che, T.; Nikolajsen, L. F.; Huang, X.-P.;
Wu, Y.; Shen, L.; Bjorn-Yoshimoto, W. E.; Ding, K.; Wacker, D.; Han,
G. W.; Cheng, J.; Katritch, V.; Jensen, A. A.; Hanson, M. A.; Zhao, S.;
Gloriam, D. E.; Roth, B. L.; Stevens, R. C.; Liu, Z.-J. 5-HT2C Receptor
Structures Reveal the Structural Basis of GPCR Polypharmacology.
Cell 2018, 172, 719−730.
(21) Chien, E. Y. T.; Liu, W.; Zhao, Q.; Katritch, V.; Han, G. W.;
Hanson, M. A.; Shi, L.; Newman, A. H.; Javitch, J. A.; Cherezov, V.;
Stevens, R. C. Structure of the Human Dopamine D3 Receptor in
Complex with a D2/D3 Selective Antagonist. Science 2010, 330,
1091−1095.
(22) Samanta, S.; Lim, T. L.; Lam, Y. Synthesis and in vitro
Evaluation of West Nile Virus Protease Inhibitors Based on the 2-{6-
[2-(5-Phenyl-4H-{1,2,4]triazol-3-ylsulfanyl)acetylamino]-
benzothiazol-2-ylsulfanyl}acetamide Scaffold. ChemMedChem 2013, 8,
994−1001.
(23) Cho, S. J.; Jensen, N. H.; Kurome, T.; Kadari, S.; Manzano, M.
L.; Malberg, J. E.; Caldarone, B.; Roth, B. L.; Kozikowski, A. P.
Selective 5-Hydroxytryptamine 2C Receptor Agonists Derived from
the Lead Compound Tranylcypromine: Identification of Drugs with
Antidepressant-Like Action. J. Med. Chem. 2009, 52, 1885−1902.
(24) Tan, L.; Yan, W.; McCorvy, J. D.; Cheng, J. Biased Ligands of
G Protein-Coupled Receptors (GPCRs): Structure-Functional
Selectivity Relationships (SFSRs) and Therapeutic Potential. J. Med.
Chem. 2018, 61, 9841−9878.
(25) Cao, J.; Slack, R. D.; Bakare, O. M.; Burzynski, C.; Rais, R.;
Slusher, B. S.; Kopajtic, T.; Bonifazi, A.; Ellenberger, M. P.; Yano, H.;
He, Y.; Bi, G.-H.; Xi, Z.-X.; Loland, C. J.; Newman, A. H. Novel and
High Affinity 2-[(Diphenylmethyl)sulfinyl]acetamide (Modafinil)
Analogues as Atypical Dopamine Transporter Inhibitors. J. Med.
Chem. 2016, 59, 10676−10691.
(26) Newman, A. H.; Beuming, T.; Banala, A. K.; Donthamsetti, P.;
Pongetti, K.; LaBounty, A.; Levy, B.; Cao, J.; Michino, M.; Luedtke, R.
R.; Javitch, J. A.; Shi, L. Molecular Determinants of Selectivity and
Efficacy at the Dopamine D3 Receptor. J. Med. Chem. 2012, 55,
6689−6699.
(27) Kroeze, W. K.; Sassano, M. F.; Huang, X.-P.; Lansu, K.;
McCorvy, J. D.; Giguere, P. M.; Sciaky, N.; Roth, B. L. PRESTO-
Tango as an Open-Source Resource for Interrogation of the
Druggable Human GPCRome. Nat. Struct. Mol. Biol. 2015, 22,
362−369.
(28) Sastry, G. M.; Adzhigirey, M.; Day, T.; Annabhimoju, R.;
Sherman, W. Protein and Ligand Preparation: Parameters, Protocols,
and Influence on Virtual Screening Enrichments. J. Comput.-Aided
Mol. Des. 2013, 27, 221−234.
(29) Genheden, S.; Ryde, U. The MM/PBSA and MM/GBSA
Methods to Estimate Ligand-Binding Affinities. Expert Opin. Drug
Discovery 2015, 10, 449−461.
